

**AWARD NUMBER:** W81XWH-14-1-0609

**TITLE:** Studying the Immunomodulatory Effects of Small Molecule Ras-Inhibitors in Animal Models of Rheumatoid Arthritis

**PRINCIPAL INVESTIGATOR:** Itamar Goldstein

**RECIPIENT:** Tel Aviv University  
TEL AVIV **Israel**

**REPORT DATE:** October 2017

**TYPE OF REPORT:** Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** "Approved for Public Release"

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE		Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>			
1. REPORT DATE (DD-MM-YYYY) October 2017	2. REPORT TYPE Annual	3. DATES COVERED (From - To) 30 Sep 2016 - 29 Sep 2017	
4. TITLE AND SUBTITLE  Studying the Immunomodulatory Effects of Small Molecule Ras-Inhibitors in Animal Models of Rheumatoid Arthritis		5a. CONTRACT NUMBER	
		5b. GRANT NUMBER W81XWH-14-1-0609	
		5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Itamar Goldstein, Yoel Kloog, Ronit Pinkas-Kramarski Morad Zayoud, Galit Elad Sfadia, Itzhak Ben Moshe, Einav Vax. E-Mail: itamargo@post.tau.ac.il		5d. PROJECT NUMBER	
		5e. TASK NUMBER	
		5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  TEL AVIV UNIVERSITY, Ramat-Aviv, Tel Aviv 69978, ISRAEL		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel  Command Fort Detrick, Maryland		10. SPONSOR/MONITOR'S ACRONYM(S) USAMRMC	
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			
13. SUPPLEMENTARY NOTES			
14. ABSTRACT During the three year of the award, our major research achievements/findings were as follows: (i) Farnesylthiosalicylic acid (FTS) therapy, a first-in-class oral selective RAS inhibitor, provides a significant immunomodulatory effect in the rat adjuvant-induced arthritis (AIA) model by all clinical and laboratory outcome parameters. (ii) Therapy with FTS as an add-on to the drug methotrexate (MTX) provides a superior protective effect compared to monotherapy. (iii) In the AIA model the FTS derivative, F-FTS, showed higher therapeutic efficacy compared to FTS. (iv) The functional genomics studies showed that FTS therapy inhibits the in vivo TH17 immune response. (v) FTS semi-prophylactic therapy in the mouse collagen-induced arthritis (CIA) model was highly effective and equal to MTX therapy. (vi) FTS and F-FTS were equally effective therapies in the CIA model and FTS monotherapy was non-inferior to combined FTS+MTX therapy. (vii) The therapeutic effect of FTS treatment in the CIA model was also coupled with attenuation of the in vivo IL-6, IL-17 and IL-22 cytokines (Th17 type) response to pathogenic autoantigens. In conclusion: our original findings strongly imply that oral selective RAS inhibitors are potent inhibitors of the TH17-driven autoimmune response in animal models of RA, signifying a strong translational horizon for these compounds.			
15. SUBJECT TERMS Ras GTPases; Rheumatoid Arthritis (RA); Farnesylthiosalicylic acid (FTS); T helper cells, disease-modifying anti-rheumatic drugs (DMARDs); targeted synthetic DMARDs			

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER <i>(include area code)</i>
U	U	U	UU	56	

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18

## **TABLE OF CONTENTS**

	<b>Page</b>
<b>1. Introduction</b>	<b>5</b>
<b>2. Keywords</b>	<b>5</b>
<b>3. Accomplishments</b>	<b>5</b>
<b>4. Impact</b>	<b>31</b>
<b>5. Changes/Problems</b>	<b>33-34</b>
<b>6. Products</b>	<b>34-36</b>
<b>7. Participants &amp; Other Collaborating Organizations</b>	<b>36-38</b>
<b>8. Special Reporting Requirements</b>	<b>38</b>
<b>9. Appendices</b>	<b>attached PDF document</b>

- 1. INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

Ras GTPases are molecular switches that regulate key cellular processes and in T cells they are necessary for proper TCR and CD28-dependent activation following antigen recognition. Reduced Ras signaling has been associated with T cell anergy and defective IL-2 production (1, 2). Importantly, synovial T cells from patients with RA display augmented activation of the Ras/Raf/ ERK pathway (3). Thus, Ras GTPases appear to be a promising molecular target for inhibiting T cell activation in RA. Based on an innovative concept Kloor (the partnering PI) and colleagues discovered (4) a potent non-toxic inhibitor of Ras, Farnesylthiosalicylic acid (FTS). In collaboration with Concordia Pharmaceuticals Inc., FTS was developed into an oral drug, Salirasib®. The drug was already tested in the clinic for the treatment of cancers with oncogenic mutations in KRAS and NRAS. No dose-limiting toxicities or major adverse events were reported during Salirasib® treatment, in phase I clinical trials of patients with advanced solid cancer. Thus, Salirasib® is the only available successful Ras GTPase inhibitor that reached clinical trials, which moreover received an orphan drug designation by the FDA for the treatment of pancreatic cancer (5, 6). In this project, our objective was to complete the following tasks:

- (i) Test in the rat AIA model of RA (rheumatoid arthritis) the prophylactic and therapeutic efficacy of FTS on relevant clinical outcomes and immunological parameters.
- (ii) Validate in CIA mouse model the prophylactic/therapeutic effects of FTS and the FTS derivative F-FTS.
- (iii) Test the effect of FTS as an add-on therapy to MTX in the AIA and CIA models.
- (iv) To explore in vitro the effects of FTS and its derivative F-FTS on a wide range of mouse T cell functions.

- 2. KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Ras GTPases; Rheumatoid Arthritis (RA); Farnesylthiosalicylic acid (FTS); Adjuvant-induced Arthritis (AIA); T cells; T-helper cells, T regulatory cells (Treg), disease-modifying antirheumatic drugs (DMARDs); targeted synthetic DMARDs (tsDMARDs).

- 3. ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.

**What were the major goals of the project?**

*List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.*

**Major Task 1:** Studying the immunomodulatory effects of the small molecule Ras-inhibitor Farnesylthiosalicylic acid (FTS/Salirasib) and its derivatives in the adjuvant-induced arthritis (AIA) rat model. **100% completion.**

**Major Task 2:** To validate in the collagen induced arthritis (CIA) DBA/1 mouse model the prophylactic/therapeutic effects of FTS and FTS derivatives. **80% completion.**

**Major Task 3:** To test the effect of FTS as an add-on therapy to MTX in the AIA rat model. **100% completion.**

**Major Task 4:** To study in vitro the effects of FTS and its derivative (F-FTS) on a wide range of mouse T cell functions and signaling networks following TCR stimulation. **50% completion** - to be achieved in full during the 4<sup>th</sup> year (approved extension period at no cost).

**Milestone #1:** Write and publish a co-authored manuscript on the therapeutic value of Ras inhibitors in the AIA and CIA models. This milestone was accomplished on time during this reporting period (months 21-33 per SOW). **100% completion.**

**Journal publications:** We published a comprehensive manuscript in *Frontiers in Immunology* that is a leading journal in its field and the official Journal of the International Union of Immunological Societies (IUIS). This multidisciplinary open-access journal publishes only rigorously peer-reviewed research across basic, translational and clinical immunology and has an excellent impact factor of 6.43.

1. Zayoud M, et al. *Front Immunol* 2017. 8:799. doi:10.3389/fimmu.2017.00799 (See attached manuscript reprint in appendix) (1).

**Conference papers:** We also presented our accomplishments in two prominent international meetings in the fields of Rheumatology (EULAR 2017) and Immunology (IMMUNOLOGY 2017<sup>TM</sup>), as detailed in item 6 of the report.

1. Zayoud M, et al. Farnesylthiosalicylic acid reduces disease severity in the collagen type-II induced arthritis mouse model by inhibiting Ras Signaling in pathogenic T cells. *The Journal of Immunology* 2017. 198(1 Supplement):224.227-224.227 (2).

2. Zayoud M, et al. RAS SIGNALING INHIBITION ATTENUATES ARTHRITIS IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY DOWN MODULATING THE PATHOGENIC TH17 CELL RESPONSE. *Annals of Rheumatic Diseases* (EULAR conference Supplement) 2017. doi: 10.1136/annrheumdis-2017-eular.2843 (3).

**Milestone #2:** Co-authored comprehensive manuscript describing the mechanisms (cellular and molecular) that control/mediate the therapeutic (Immunomodulatory) effects of small molecule Ras inhibitors in the AIA and CIA animal models of RA, including mechanistic data derived from the in vitro work in Task 4. **To be completed**, per approved current SOW, during the approved no-cost extension of 12 months of award performance period (**to be completed on months 42-48**).

**What was accomplished under these goals?**

*For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.*

**OVERALL PROJECT SUMMARY (First, Second and Third Year):**

In **Major Task 1** of the revised SOW, we determined in the Lewis rat AIA model of the prophylactic and therapeutic effects of FTS.

**Subtask 1A:** Analyze the prophylactic/therapeutic effects of FTS on clinical AIA progression and joint pathology (**months 1-15, completed**).

As detailed in the interim Technical reports of the first and second year, we have already defined the clinical effects of prophylactic dosing of FTS and its derivative F-FTS on the progression of AIA in Lewis rats. In this set of experiments, we compared the therapeutic effects of the oral Ras-inhibitors to treatment with a conventional DMARD, methotrexate (MTX). Adjuvant induced arthritis in Lewis rats is an experimental model of polyarthritis that has been extensively employed for preclinical testing of numerous anti-arthritic agents. The arthritis is induced by injection of an arthrogenic preparation of complete Freund's adjuvant (CFA), prepared by suspending powdered heat-killed *Mycobacterium tuberculosis* in mineral oil at 10 mg/ml. The hallmark of this model is consistent onset and progression of robust and easy to measure polyarticular inflammation associated with marked tissue/synovial inflammation and subsequent articular bone resorption (4). In our hands, in agreement with previous works, clinically evident arthritis of the ankle joint usually developed ~9-11 days' post CFA injection that progressed, in untreated control animals, into severe poly-arthritis within a few days.

We employed two dosing models:

- Prophylactic – start on day +1 and continue until the end of experiment.
- Therapeutic – start on disease onset (day +9) until study termination.

**Clinical Assessment:** To assess disease progression, both clinical scoring (0-4 scale for each paw, 0-16 scale for total arthritis severity) and caliper measurements of ankle joint width were used, as previously described.

**Histopathological Assessment:** At study termination, the tibiotarsal joint was transected at the level of the medial and lateral malleolus for Histopathological Assessment. Ankle joints were then collected into 10% paraformaldehyde, for at least 24 hours, and then placed in a decalcifier solution. When decalcification was completed, the ankle joint was transected in the longitudinal plane and joints were processed for paraffin embedding, sectioned and stained with hematoxylin & eosin. Arthritic ankles were then given scores on a scale of 0-5 for inflammation and bone resorption by an experienced pathologist blinded to the animal treatment protocol, as previously described (4).

i. As detailed in the previous interim reports, we determined the clinical efficacy of prophylactic dosing with FTS suppresses the clinical signs of AIA. In the experimental arm, we started daily treatment with oral FTS (100 mg/kg) from day +1 post CFA immunization. Control rats received oral vehicle solution of 0.5% carboxy methyl cellulose (CMC). In the MTX arm, the rats were given weekly *i.p* injection of MTX (0.5 mg/kg). AIA progression and severity was scored using the clinical index of 0 to 16. In parallel, we also assessed disease progression by caliper measurements of ankle joint width prior to the onset of arthritis, and then every other day until the study termination on day +21 post CFA injection. We found and reported in the previous interim report and our recent publications (1, 3) that the arthritis scores and ankle inflammatory swelling were significantly reduced by FTS treatment group compared to CMC vehicle treated rats. Importantly, we also found that the clinical effect of FTS, assessed by the above outcomes measure, was non inferior to MTX therapy. **Responsible PI: Yoel Kloog, Tel Aviv University.**

ii. We also previously found that the histopathological assessment of Ankles of arthritic CMC vehicle treated rats showed extensive infiltration of joints tissue with mononuclear cells (inflammation scores ranging from 4 to 5, n=8), and significant bone destruction (bone resorption scores ranging from 4 to 5). In contrast, the histopathological assessment of joint sections from FTS-treated rats showed significant reduction in joint inflammation (inflammation scores ranging from 2 to 3, n=8), and significantly less destruction of trabecular and cortical bone in the distal tibia (bone resorption scores ranging from 2 to 3). **Responsible PI: Yoel Kloog, Tel Aviv University.**

iii. We also performed immunohistochemistry assessment of deparaffinized and rehydrated arthritic rat ankle joint sections for the infiltrations of T lymphocyte into the synovial tissue, as detected using anti-CD3 antibodies. Our findings (reported on 2<sup>nd</sup> year report), were that the arthritic joints of CMC vehicle treated rats displayed extensive infiltration of the synovial tissue with CD3+ T cells that was significantly reduced in the joints of FTS treated mice (data not shown). This implies that FTS and its derivative target the T cell response and subsequent homing into target synovial tissues.

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

iv. The FTS derivative, 5-Fluoro-FTS (F-FTS), has been previously shown by studies from Prof. Kloog's lab to be a highly potent immunomodulatory drug (5). Thus, during the second year of the project, we investigated more broadly the relative therapeutic efficacy of F-FTS.

In a set of experiments comparing "head-to-head" the clinical effects of F-FTS vs. FTS, we found that prophylactic dosing with F-FTS (60mg/kg) from day +1 post CFA injection had a significant therapeutic effect on the clinical outcome of AIA without obvious *in vivo* toxicity. The efficacy of F-FTS was indeed superior compared to FTS treatment ( $P < 0.05$  by one-way ANOVA and post-hoc Bonferroni's Multiple Comparison Test (see relevant data in 2<sup>nd</sup> year report and recent publication (1)).

**Responsible PI: Yoel Kloog, Tel Aviv University.**

v. As we reported in the 2<sup>nd</sup> year, we next tested the efficacy of FTS when the treatment was given in the "therapeutic scheme" from day +9 (onset of arthritis in the hind paws). We found that therapeutic dosing of FTS did not effectively reduce disease severity as measured by both clinical disease scoring and ankle swelling per caliper measurements. As expected,



dexamethasone therapeutic dosing (positive control) was effective in decreasing the severity of AIA compared to CMC vehicle treatment ( $p < 0.01$ ). Additionally, in a single exploratory study we also tested FTS as an add-on therapy to MTX (0.5mg/kg) in the therapeutic dosing model compared to this combined treatment in the prophylactic protocol. We found that while prophylactic FTS+MTX dosing almost completely prevented arthritis development, the therapeutic FTS+MTX dosing schedule had no significant effects on disease outcome measures. During the current reporting period we also performed a single exploratory study to test the efficacy of F-FTS in the therapeutic-dosing-scheme, also with negative results (data not shown). Thus, our data imply that this latter dosing scheme is imprecise for predicting the "true" therapeutic potential of certain agents in RA. **Responsible PI: Yoel Kloog, Tel Aviv University.**

**Subtask 2B:** To analyze the effects of FTS treatment on the cytokine profile and relevant isolated T cell subsets including, TH17, TH1 and Foxp3+ regulatory T cells and related molecular markers (**months 4-15**).

**vi.** Next, we analyzed the effects of the various treatment protocols on the immune response to CFA, particularly on the CD4+ T cell response. At study termination both peripheral blood samples and spleens were collected and analyzed by flow cytometry for treatment effects on major lymphocytic populations. As detailed in previous reports, we observed a trend towards an increased CD4+ to CD8+ T cell ratio in the spleens of FTS treated rats compared to control rats. This effect was likely due to a statistically significant increase in the percentage of CD4+ Foxp3+ regulatory T cells (Treg) in the spleens of FTS treated rats (see relevant figures in previous reports). As both TH1, TH17 and double positive TH1/Th17 cells have been postulated to be instrumental in the pathogenesis of T cell dependent autoimmune responses, both in animal models and humans, we analyzed the effects of FTS and other treatments on the induction of these T cell subsets in arthritic rats. Our data show that FTS therapy was associated with significantly lower numbers of TH17 and TH1/TH17 cells in the spleens of treated rats compared to CMC vehicle treated mice. This effect was even more significant when we administered FTS, as an add-on therapy to MTX, with strong positive correlation with the clinical outcome data (see also recent publications (1-3)).

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**vii.** In accordance with the intracellular cytokine detection data, we also found that on day +14 both FTS and MTX alone typically reduced serum IL-17 levels by ~50%, whereas the combined treatment of FTS+MTX reduced IL-17 levels even more significantly by >90%, as compared to CMC control treated arthritic rats. We also found that CFA injection indeed induced a substantial increase in CRP levels in CMC vehicle treated arthritic rats. In contrast, the combined FTS+MTX completely abolished this increase at the two-time points (day +10 and +14 of the study). While both FTS and MTX reduced CRP levels at day +10, they were less effective, as a single agent, in suppressing the induction of CRP on day +14. Moreover, our CRP data show that it directly correlated with the extent of target tissue inflammation (ankle diameter) that was strongly inhibited by the combined treatment (See relevant data and figures in the 2<sup>nd</sup> year report and publications).

**Responsible PI: Yoel Kloog, Tel Aviv University.**

**viii.** As detailed in previous reports, we studied the *in vitro* cytokine response to re-stimulation with the pathogenic mycobacterial antigen Bhsp65. Thus, on day +12, after the onset of clinical arthritis, spleens and draining superficial inguinal and para-aortic lymph nodes (LNs) were harvested and a single-cell suspension of a mixture of spleen and LN cells was obtained. Subsequently, the isolated cells were cultured at 37°C for 5 days in a six-well plate ( $5 \times 10^6$  cells/well) with or without Recombinant mycobacterial Bhsp65 protein (5µg/ml), as previously described (6). We detected a strong induction of IL-17 secretion following *in vitro* antigenic re-stimulation with Bhsp65, principally in the T cell cultures of untreated mice. Importantly, *in vivo* prophylactic FTS and F-FTS treatment resulted in significant reduction Bhsp65-specific IL-17 secretion compared to control CMC treatment. Moreover, F-FTS treatment was more effective in the suppression of the pathogenic antigen-specific IL-17 response (Figure 2). **Responsible PI: Yoel Kloog, Tel Aviv University.**

**xiii.** In accordance with the revised current SOW, to gain a more comprehensive insight into the "molecular mechanism" that mediate the therapeutic action of small molecule Ras-inhibitors in AIA, we analyzed the changes in gene expression (mRNAs) mediated by FTS and F-FTS treatment in pure CD4<sup>+</sup> T cells by GeneChip arrays. Thus, at the end of the *in vitro* antigenic re-challenge, as detailed above, we harvested the cells and isolated the CD4<sup>+</sup> T cell population using Rat CD4 MicroBeads and the MACS cell separation platform (Miltenyi Biotec, Germany), according to the manufacturer's instructions. The purified CD4<sup>+</sup> T cells were lysed with the TRIzol® Reagent (Invitrogen, Inc.), and total high quality RNA was purified using the Direct-zol™ RNA Kit (Zymo Research Corporation) for subsequent downstream analysis. Gene expression was determined using the GeneChip® Rat Gene 2.0 ST Array System (Affymetrix, Inc.), according to the manufacturer's instructions. Gene level RMA sketch algorithm was used for crude data generation (Affymetrix Expression Console and Partek Genomics Suite 6.2). Genes were analyzed using unsupervised hierarchical cluster analysis (Spotfire DecisionSite for Functional Genomics; Somerville, MA, USA) to get a first assessment of the data, and filtered according to fold change calculations. The primary microarrays data from this research have been deposited in the NCBI Gene Expression Omnibus data repository under accession number GSE100280.

The results of the advanced bioinformatics analysis of the various CD4<sup>+</sup> T cell samples revealed that the antigenic re-stimulation with Bhsp65, as expected, induced a robust upregulation of multiple ( $n = 50$ ) genes in CD4<sup>+</sup> T cells (see previous report and Figure 5 in our recently published manuscript). Importantly, the analysis of the signal intensity of this list of Bhsp65-induced differentially expressed genes in CD4<sup>+</sup> T cells of FTS vs. CMC treated rats ( $\geq 2$  fold-change), revealed a widespread FTS-dependent reduction in the intensity of the Bhsp65-induced transcription of a large percentage of these 50 genes ( $P < 0.001$ , by chi-square test). Notably, this list included a large number of acknowledged immune response genes, such as genes encoding pro-inflammatory cytokines (e.g., Il22, Il17a/f, Ifng, Csf2/GM-CSF, Lta, and Il1a).

Next, to determine, in unbiased manner, the biological processes and molecular functions that mediate the therapeutic effect of FTS, we performed additional in-depth bioinformatics analysis. Thus, we computed the overlaps between our gene list and relevant annotated gene sets within the HALLMARK and gene ontology (GO) collections of the Molecular Signatures Database of

the Broad Institute (Massachusetts Institute of Technology) using the GSEA software web site v6.1. <http://software.broadinstitute.org/gsea/msigdb/index.jsp> By this analysis, we determined that the list of genes upregulated significantly ( $\geq 2$ -fold change, FDR  $q < 0.05$ ) following Bhsp65 re-stimulation of CD4<sup>+</sup> T cells isolated from CMC treated control rats exhibited significant overlap with a large number of curated relevant immune response and cell proliferation gene sets. The top overlapping annotated gene sets included: (i) cytokine activity (GO); immune system processes (GO); G2M\_checkpoint (HALLMARK); inflammatory response (HALLMARK); response to tumor necrosis factor (GO); response to IFN-gamma (GO); positive regulation of cell proliferation (GO); IL6\_JAK\_STAT3\_signaling (HALLMARK); K-RAS signaling up (HALLMARK); and others (see Figure 5B in our recently published manuscript). To validate our GeneChip® data, we analyzed by qPCR the relative quantity of mRNA transcripts of five highly relevant inflammatory response genes differentially induced by Bhsp65 re-stimulation in CMC vs. FTS treated CD4<sup>+</sup> T cells (ccl20, il22, il17A, il17F, and Csf2). Our results, confirmed that the induced transcription of all these genes, during the recall response of TH17 cells to Bhsp65, was significantly inhibited by FTS therapy ( $P < 0.05$ , by t-test). Moreover, we also validated in relevant culture supernatants, by ELISA kits, a strong induction of IL-17A and IL-22 protein expression following in vitro Bhsp65 re-challenge that was significantly inhibited by in vivo FTS therapy.

In conclusion, bioinformatics of the transcriptomics data, indeed, allowed us to gain further insight into the biology behind the effect of FTS. Namely, down modulation of the *in vivo* induction of a pathogenic TH17 response (IL-22- and IL-17-driven) to CFA/Bhsp65 (See also relevant data and figures in the 2<sup>nd</sup> year report and our recent paper (1)).

**Responsible PIs: Itamar Goldstein & Yoel Kloog, Tel Aviv University.**

In **Major Task 2** of the revised SOW we proposed to validate in collagen induced arthritis mouse model the prophylactic/therapeutic effects of FTS and its derivative, F-FTS.

**Subtask 2A:** Analyze the prophylactic/therapeutic effects of FTS and F-FTS on the clinical scoring, histopathology of ankle joints, and serum IL-17A/IL-6 levels at arthritis onset (**months 16-42**).

CIA is the most widely studied animal model of RA, as it shares several pathological features with RA, and Collagen type-II is (CII) is a major antigen in human cartilage, the target tissue of RA. This model has been used widely to identify potential pathogenic mechanisms of autoimmunity relevant to RA, including the role of specific T cell subsets in disease pathogenesis and progression, as well as to design and test new drugs and therapeutic modalities. For example, the CIA model has been instrumental in the testing and development of the new biologically based therapeutics, such as those that target the pathogenic cytokines TNF, IL-6 and IL-17 produced by macrophages and T cells that are the dominant immune cell mediators of RA pathogenesis. CIA can be established in the genetically susceptible, DBA/1 (H-2q) mouse strain, by immunization with CII emulsified in CFA (on study day 0 and 21). The ensuing pathogenesis shares several clinical and immunological features with RA, including synovial hyperplasia, mononuclear cell infiltration, cartilage degradation, and like RA, the disease is dependent on MHC class II genes and T cells. In our hands, in agreement with previous studies, clinically evident arthritis of the ankle joint usually developed ~10 days after the second booster

immunization with CII (namely ~30-32 days after the primary immunization), which progressed, in control animals, into severe polyarthritis within a few days.

We employed two dosing schemes:

- Semi Prophylactic – start dosing 3 days before booster immunization until study end.
- Therapeutic – start dosing at arthritis onset (~ day +30) until study end.

Clinical Assessment: Disease progression was assessed by a clinical scoring index (0-16 scale) starting at arthritis onset and subsequently every other day until study termination.

i. In the previous reporting period, we performed initial studies to determine whether prophylactic dosing with FTS attenuated the clinical signs of CIA, and also assessed its "effect size" compared to a recognized DMARD, MTX. The preliminary observation suggested that FTS was a highly potent therapy that was at least as effective as MTX therapy. In this reporting period we also compared the clinical efficacy of the FTS derivative, 5-Fluoro-FTS (F-FTS), against both FTS and MTX in the CIA model. Thus, 8-week-old DBA/1 male mice were given an initial injection of type 2 collagen on day 0, and arthritis was induced with a second injection on day 21. Mice in the three experimental arms were treated starting day +18, as follows: (i) FTS at 100mg/kg daily; (ii) F-FTS at 60mg/kg daily; or (iii) weekly i.p injection of MTX (1 mg/kg). Mice treated with CMC vehicle solution served as controls. CIA severity was scored using a clinical index of 0 to 16 (0-4 scale for each paw). Our results from these large experiments were that F-FTS therapy was non-inferior to FTS and MTX therapies. Although, FTS displayed a trend towards being more potent than F-FTS in its clinical efficacy, the effect did not reach the statistical threshold of  $P < 0.05$  (Figure 1).

Given these data and our ethical duty to balance the needs of the study with that of the animals' welfare, in compliance with the principle of reduction (per USAMRMC ACURO guidelines), we decided that we will concentrate on FTS as the lead compound to be investigated in the CIA model. Thus, in current reporting period, we focused on expanding and repeating the experiments assessing the clinical efficacy of FTS vs. no active drug (0.5% CMC vehicle). We found that FTS monotherapy was very efficacious, considerably reducing arthritis scores compared to CMC treated mice (Figure 2A). Importantly, the area under curve (AUC) of the clinical scores of mice in the active drug treatment arm was significantly reduced, by ~80%, compared to the control arm (Figure 2B;  $P < 0.001$  for FTS vs. CMC by Student's t-test).

***Responsible PIs: Itamar Goldstein & Yoel Kloog, Tel Aviv University.***

ii. For Histopathological Assessment at study termination, the tibio-tarsal joint was transected at the level of the medial and lateral malleolus. Next, we collected the ankle joints into 4% paraformaldehyde for at least 24 hours and then placed them in a decalcifier solution. When decalcification was completed, we transected the ankle joints in the longitudinal plane and the joints were paraffin embedded, sectioned and stained with hematoxylin & eosin (Figure 3A). Next, an experienced pathologist, blinded to the animal treatment protocol, scored the various joint sections on a scale of 0-5 for inflammation, pannus formation and bone resorption (Figure 3B), as previously described (4). Our pathology scoring results show that while immunization against CII in control animals induced extensive tissue inflammation, pannus formation and bone resorption (all with an average scores  $> 4$ ), the therapy with FTS significantly reduced joint pathology scores for all these three parameters (all with an average score  $< 1.5$ ).

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**iii. (a)** The titers of anti-CII antibody are a very useful parameter/marker to probe for effective immunization and the induction of T cell-dependent CII-specific autoreactive pathogenic B cells (7). Thus, by a readymade "gold standard" anti-CII IgG ELISA kit (Chondrex, Inc., USA) we determined in the sera of mice from the various treatment groups the relative levels of these pathogenic autoantibodies. Our results (Figure 4A) show that FTS therapy significantly inhibited the induction of a prominent anti-CII antibody response post immunization with CII and adjuvants ( $p < 0.001$ , for both time points, by Student's t-test).

**(b)** Previous studies have suggested that auto-antibodies against self citrullinated proteins are centrally involved in the pathogenesis of rheumatoid arthritis, and it was reported that polyclonal antibody responses to anti-citrullinated proteins, found in joints, develop in the early stages of CIA creating neo-antigens that further boost the "epitope spreading" during the autoimmune response(8). Therefore it was very informative to analyze the effect of FTS therapy on the induction of such anti-citrullinated peptide antibodies (ACPA). By clinical-grade commercial ELISA kits we tested sera, collected at day +48 post immunization, from actively treated and control mice. Our finding (Figure 4B) clearly show that FTS therapy resulted in a significant reduction in the levels of ACPA ( $P < 0.001$  for FTS vs. CMC, by Student's t-test). This observed strong positive correlation between these two validated immunological disease-relevant parameters/markers and the clinical scoring data further confirms our working hypothesis that FTS is a potent anti-arthritis drug.

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**iv.** The cytokines IL-6 and IL-17 have been shown to mediate and mark the systemic inflammation and arthritis in rodent models (9, 10). Importantly, our published results in the AIA model indicate a substantial inhibition of the IL-6 driven TH17 response to be a major mechanism of action for FTS and F-FTS therapy (1). In this reporting period, we also probed the effect of FTS on the induction of these autoimmunity-relevant cytokines in the CIA model of RA. Thus, sera from FTS and vehicle CMC treated mice were collected at day +33, at the onset of arthritis, and analyzed for IL-17A and IL-6 levels by ready-made ELISA kits. (eBioscience Inc.). We find that at the early stages of arthritis development FTS significantly reduces the upregulation of IL-6 observed in the control arm (~60% inhibition,  $p < 0.001$  by Student's t-test). More importantly, FTS therapy completely suppresses IL-17 induction to below the detection limit of the ELISA kit compared to  $>60\text{pg/ml}$  levels in the control mice (Figure 4C). This observation strongly indicates that the suppression of the IL-6-dependent TH17 response is an important general mechanism of action for our novel small molecule Ras-inhibitors, as we show in the two animal models of rat AIA and mouse CIA.

**Responsible PI: Yoel Kloog, Tel Aviv University.**

**Subtask 2B:** Analyze the effects of the Ras inhibitors on relevant immune cells and T cell subsets including FOXP3+ Treg and TH17 cells, the cytokines response by multiplex analysis, and relevant molecular markers such p-AKT and p-ERK, and (**mo. 16-45**).

**v.** In this reporting period, we expanded the analysis of the effects of FTS treatment on the "major" lymphocytic cell populations. Thus, at study end we harvested spleens and prepared

single cell suspensions for downstream polychromatic flow cytometry analysis. The cells were next immunostained for the markers CD3, B220, CD4 and CD8. We found that neither CFA/CII immunization by itself nor the treatment protocol (FTS vs CMC) result in a significant effect on the percentage of total CD3<sup>+</sup> T cells, total B cells, and the ratios of CD4<sup>+</sup> to CD8<sup>+</sup> T cells in the spleen as compared to naïve mice (Figure 5A-D). **Responsible PI: Itamar Goldstein, Tel Aviv University.**

**vi.** During the previous reporting period, in initial experiment, we used the Luminex xMAP bead-based multiplex immunoassay technology to gain a comprehensive insight into the effect of FTS treatment on the CII-specific TH cell-dependent cytokine response. Thus, we first prepared a single cell suspension from spleen and lymph node cells of mice immunized with CII and treated with oral FTS or CMC vehicle. The various cell samples were immediately stimulated with the relevant T cell pathogenic antigen, heat denatured bovine CII (from Chondrex Inc.), and the cells were cultured for 72 hours. At the end of culture, the supernatants were collected and we determined the induction of a large number of relevant cytokines, using the ProcartaPlex Mouse Th1/Th2/Th9/Th17/Th22/Treg Cytokine Panel (17 analytes), per manufacturer's recommendations (eBioscience Inc.). We found that the re-stimulation of CII-specific effector T cells from immunized untreated arthritic mice (CMC control treatment arm) induced a strong upregulation of many autoimmunity related cytokines (IL-6, TNF, GM-CSF, IFN- $\gamma$ , IL-9, IL-17A, and IL-22). Importantly, this induction was significantly inhibited in T cells from mice treated with FTS.

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**vii.** Ample evidence indicates that TH17 cells are required for initiation and progression of autoimmune arthritis both in the mouse CIA model and in patients with RA (11). Th17 cells also secrete IL-22, a cytokine generally considered as pro-inflammatory in the context of RA and its levels are elevated in the blood and synovia of RA patients (12). Mice deficient in IL-22 are less susceptible to CIA and IL-22 can induce proliferation of synovial fibroblasts and promote the generation of osteoclasts, and more recently it was reported that IL-22 plays a pathogenic role during the initiation phase in CIA (13-15). As our multi-Plex data indicated a strong induction of IL-17 and IL-22 during CIA development, we focused in the current reporting period, on the effect of FTS therapy on the important effector population of IL-17A and IL-22 producing TH17 cells. At study end (day +45), single-cell suspensions of splenocytes and inguinal lymph nodes (LN) were prepared by mechanical disaggregation followed by lysis of red blood cells. For intracellular cytokine staining, the isolated lymphocytes were activated for 5 hrs, ex vivo, with Cell Stimulation Cocktail reagent in the presence of a commercial Protein Transport Inhibitor Cocktail, according to the manufacturer's protocol (all reagents from eBioscience). After harvesting, T cells were surface stained with flouochrome conjugated anti-mouse CD3 and CD4 mAbs, washed, fixed, and permeabilized using BD Cytofix/Cytoperm™ kit, per manufacturer's instructions (BD Biosciences). Intracellular staining was performed with flouochrome conjugated mAbs against IL-17A and IL-22 (from eBioscience). The results of the intracellular staining showed a significant reduction in the percentage of IL-17A/IL-22 double positive TH17 cells and IL-22<sup>+</sup> single positive TH cells in FTS treated mice compared to relevant control mice (Figure 6). Interestingly, our results did not demonstrate a significant change in the numbers of IL-17 single positive TH17 cells in the samples of FTS treated mice. These original findings

imply that targeting the induction of IL-22 expression in TH17 cells is a relevant mechanism of action for FTS therapy.

**Responsible PIs: Itamar Goldstein & Ronit Pinkas-Kramarski, Tel Aviv University.**

**viii.** In addition, we also analyzed specifically the antigen-specific recall response to CII, directly linked to the pathogenesis of CIA. Thus, 8-12-week-old DBA/1 male mice were immunized with CII in CFA, and treated from Day +1 with oral FTS or control CMC vehicle for 10 days. At the end of study, spleens were collected, processed into a single cell suspension, and splenocytes were labeled with the CFSE dye. The cells were then stimulated *in vitro* with heat denatured bovine CII (Chondrex Inc.) or control medium and culture for additional 96 hrs. Our results conclusively show that the proliferation of CD4<sup>+</sup> T cells, as determined by the CFSE-dye dilution flow cytometric assay, was significantly reduced in cultures from FTS vs. CMC treated mice (Figure 7A). Likewise, the ELISA of IL-17 supernatants that were collected from these cultures highlighted the strong suppression of the *in vivo* induction of the TH17 response to CII. We found that FTS therapy was associated with a significantly reduced secretion of IL-6, IL-22 and IL-17A, as compared to relevant control cultures (Figure 7B). Taken together these new data allow us to conclude that FTS is a potent suppressor of the TH17 response to CII immunization – central to the pathogenesis of CIA.

**Responsible PIs: Itamar Goldstein & Ronit Pinkas-Kramarski, Tel Aviv University.**

**ix.** As the balance between the inductions of antigen-specific pathogenic TH17 versus peripheral CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Treg) can influence the outcome of the T cell response to self-antigens (16), we also determined, during the previous reporting period, the percentage of Treg cells in the spleens of the various mice groups. Our results show that FTS therapy was associated with significantly increase in Foxp3<sup>+</sup> Treg cells percentage in the spleens of treated rats compared to CMC vehicle treated mice (see relevant data in 2<sup>nd</sup> year technical report). Importantly, the ratio of Treg to Th17 cells was significantly increased ( $P < 0.01$ ) in FTS vs. CMC treated mice (see related text and figures in previous report). These results strongly support our working hypothesis that FTS is a potent immunomodulatory drug, potentially applicable to the treatment of human RA.

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**x.** In the second year report, we already demonstrated, as projected, that FTS therapy is coupled with effective blockade of the RAS signaling cascade in lymphocytes. We used p-ERK and p-AKT levels in splenocytes of CII immunized mice at necropsy, as molecular marker of active Ras-GTPase signaling. Our analysis of p-ERK and p-AKT levels in CD4<sup>+</sup> T cells by the Phospho-specific Flow Cytometry method proved that FTS therapy significantly reduced, *in vivo*, in freshly isolated splenic CD4<sup>+</sup> T cells both p-ERK and p-AKT levels.

**Responsible PI: Yoel Kloog & Ronit Pinkas-Kramarski, Tel Aviv University.**

In **Major Task 3**, we proposed to test the effect of FTS as an add-on therapy to MTX therapy in the AIA rat model.

Subtask 3A: Analyze the prophylactic/therapeutic effects of FTS and F-FTS on the clinical scoring, histopathology of ankle joints, and serum IL-17A/IL-6 levels at arthritis onset (**months 6-24, completed**).

**i.** As detailed in the previous reporting period and in our published manuscript and throughout the text of major task 1, we also discovered that treatment with FTS as an add-on to MTX provided a very strong protective effect, such as that the combined treatment almost completely inhibited the development of clinically-evident arthritis (clinical score) and ankle joint swelling (caliper measurements of ankle joint diameter). While monotherapy with each compound alone reduced these clinical outcome measure by approximately 50%, the combined MTX+FTS therapy reduced these disease severity parameters by >80% (see Figure 1A in the attached manuscript. The difference in efficacy of the combined FTS+MTX therapy vs. monotherapy was of statistical significance in repeated studies ( $P < 0.05$ , by one way ANOVA with post hoc Bonferroni's multiple comparison test).(1)).

**Responsible PI: Ronit Pinkas-Kramarski, Tel Aviv University.**

**ii.** To further evaluate the effects of FTS as an add-on treatment to MTX on arthritis development, we examined ankle joint sections stained with hematoxylin and eosin from the various treatment arms as detailed above. The ankles sections were given scores of 0–5 for bone resorption and inflammation, as previously described (4). As reported in our manuscript, the histological joint tissue sections from 0.5% CMC vehicle treated rats showed extensive infiltration with mononuclear cells (inflammation scores ranging from 4 to 5,  $n = 5$ ), and significant bone destruction (bone resorption scores ranging from 4 to 5). In comparison, the sections from FTS treated rats showed reduced joint tissue infiltration by immune cells (inflammation scores ranging from 2 to 3,  $n = 5$ ), and less destruction of trabecular and cortical bone in the distal tibia (bone resorption scores ranging from 2 to 3). More importantly, the tissue sections from rats treated with FTS as an add-on to MTX showed only minimal joint tissue infiltration with immune cells (average inflammation score of  $\sim 1.5$ ) and only rare areas of trabecular or cortical bone resorption not readily apparent on low magnification (average bone resorption scores of  $< 1.5$ ). This superior efficacy of the combined treatment in preventing tissue inflammation and bone damage was statistically significant as well ( $P < 0.05$ , by Student's t-test).

**Responsible PI: Itamar Goldstein & Ronit Pinkas-Kramarski, Tel Aviv University.**

**Subtask 3B:** Analyze the effects of the combined MTX and FTS treatment on the serum cytokine profile and relevant T cell subsets including TH17 cells and FOXP3+ Treg (**months 6-24, completed**). The results of this aim have been partly reported in the 2<sup>nd</sup> year as well as in our recent manuscript (see details in Milestone #1 and the paper's reprint in the appendix material).

**iii.** IL-17+ and IL-17+IFN- $\gamma$ + Th17-type cells have been shown to be instrumental for the pathogenesis of autoimmune responses (17). Thus, we determined in the second year the effects of FTS, MTX, and the combined treatment protocols on the induction of IL-17 and IFN- $\gamma$  producing TH cells in the lymphatic system (spleen) during AIA development (see Figure 2A in manuscript (17)). We find that CFA immunization in control CMC-vehicle treated rats induces a significant induction of IL-17+ ( $\sim 20$ -fold increase;  $P < 0.001$ ) and of IL-17+IFN- $\gamma$ + Th17 cells ( $4.6 \pm 0.34$  vs.  $0.04 \pm 0.01$ ,  $P < 0.01$ , by Student's t-test) compared to naive unimmunized rats. FTS monotherapy significantly reduces the induction of these pathogenic Th17 cells in the spleens of FTS treated rats compared to control CMC-vehicle treated arthritic rats ( $P < 0.001$ ). More importantly, FTS as an add-on to MTX therapy induces a more significant reduction in the percentage of the highly pathogenic IL-17<sup>+</sup> IFN- $\gamma$ <sup>+</sup> double positive TH17 cells, as compared to



either drug alone  $P < 0.01$  (see Figures 4 in published paper). Thus, the TH17 cell response data showed a positive and significant correlation with the clinical outcomes data of the various treatment protocols. Next, we analyzed the effects of FTS and the different treatments on the induction of IFN- $\gamma$  (only) TH1 cells in the spleens. We find that, in contrast to the TH17 data, CFA immunization did not produce a significant increase in splenic TH1 cells percentage compared to naive unimmunized rats. Additionally, FTS monotherapy or as an add-on to MTX did not significantly reduce TH1 cells numbers in the spleens of the various rat groups.

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

**iv.** Next, to further investigate the immunomodulatory effect of the combined treatment with MTX vs. FTS monotherapy on the TH17 response to BhSP65/CFA, we determined the levels of the key TH17 cell cytokines, IL-17A and IL-22, in serum samples collected at day 14 of the experiment. We find that monotherapy with FTS or MTX significantly reduces serum IL-17 levels compared to control CMC-treated arthritic rats ( $P < 0.001$ , by Student's t-test). Furthermore, FTS+MTX combined therapy was extra potent in suppressing IL-17 levels compared to single agent ( $P < 0.01$ ). We also find a strong upregulation of serum IL-22 at day +14 in control CMC treated rats, which is significantly inhibited by either FTS or MTX therapy ( $P < 0.001$ ). Interestingly, FTS as an add-on to MTX inhibits IL-22 production very effectively compared to MTX alone (~75% suppression by the combined FTS and MTX vs. MTX monotherapy,  $P < 0.01$ ).

**Responsible PI: Itamar Goldstein, Tel Aviv University.**

In **Major Task 4** we propose to analyze in vitro the effects of FTS and F-FTS on various T cell-signaling events and T cell differentiation programs following TCR stimulation (**months 25-42**).

**i.** In this reporting period we initiated studies to address the effects of FTS on the proliferation of T cells. Thus, we purified CD4<sup>+</sup> T cells by negative selection from spleens of naïve 8-12-week-old DBA/1 male mice, using the MACS® magnetic cell separation technology (all reagents were from Miltenyi Biotec, Germany). Next, the pure CD4<sup>+</sup> T cells were labeled with CFSE and activated by plate-bound anti-CD3 and soluble anti-CD28 (All from eBioscience Inc.) in a fully supplemented complete RPMI medium for 3 days. The cultures were treated with the indicated concentrations FTS dissolved in DMSO or vehicle alone. At the end of culture the CD4<sup>+</sup> T cells were harvested and analyzed by FACS for CFSE-dilution (Figure 8A). These data allowed us to determine the effect of the different doses of FTS on T cell proliferation. We found a significant inhibition of proliferation starting at a low concentration of 12.5 $\mu$ M and peaking at ~50 $\mu$ M of FTS (Figure 8B). Of note the inhibition was not significantly more effective at concentrations in the range of 100-150 $\mu$ M (data not shown).

**Responsible PI: Ronit Pinkas-Kramarski, Tel Aviv University.**

**ii.** Our results and major achievements in Tasks 1-3 highlight that a major *in vivo* mechanism of action of the small molecule oral Ras-inhibitors, FTS and F-FTS, is potent inhibition of the TH17 response to pathogenic antigens. Treatment with Ras-inhibitors was associated with a significant inhibition of IL-17A and IL-22 levels in the serum of actively treated animals as compared to relevant control arthritic rats. Moreover, our ELISA and transcriptomics data show that the TH17-type recall response to Bhsp65 or CII were in immunized rats and mice, respectively, were significantly diminished in T cells derived from FTS treated animals.

Importantly, the superior clinical efficacy F-FTS treatment positively correlated with its superior capacity to down modulate the pathogenic antigen-specific TH17 response (i.e. reduced IL-17 secretion).

Thus, to further study and validate these in vivo data we stimulated pure CD4<sup>+</sup> T cells with plate-bound anti-CD3 and soluble anti- CD28 and cultured them for 72 hrs. At the end of culturing, the supernatants were collected and analyzed for secreted IL-17A and IL-22 by readymade ELISA kits. Our results show that following polyclonal stimulation FTS suppressed the strong induction of the TH17-class cytokines, IL-7 and IL-22, secretion by CD4<sup>+</sup> T cells detected in control cultures. In agreement with our in vitro proliferation data, we find a significant inhibition of IL-7 and IL-22 secretion starting at a low concentration of 12.5µM. This inhibition was rather effective (>50%) at this FTS dose, with a small incremental increase at 25-50µM of FTS (Figure 8C). Once more, the inhibition of TH17 cytokines production was not significantly augmented by higher concentrations of FTS in the 100-150µM range (data not shown).

**Responsible PI:** *Itamar Goldstein, Tel Aviv University.*

#### **Other achievements:**

**i. Milestone #1: Published Manuscript** on the therapeutic value of Ras inhibitors in the AIA and CIA animal models.

As detailed in this report and previous reports, we have generated multiple clinical, immunological and molecular data clearly showing that the small molecule Ras-inhibitors, FTS and F-FTS, are potent disease modifying drugs in two major animal models of RA and that using FTS therapy as an add-on to MTX therapy significantly increased efficacy compared to monotherapy. In accordance with the SOW, during this reporting period we published a comprehensive manuscript that summarizes our novel findings (1).  
(See details in item 6 of the current report).

**ii. Conference papers and presentations:** As detailed in item 6 in the current report our data and research achievements were presents in two important international scientific conferences. IMMUNOLOGY 2017™ meeting (May 12-16, Washington, DC) and **EULAR 2017** (14-17 June, Madrid, Spain).


**Responsible PIs:** *Itamar Goldstein & Yoel Kloog / Ronit Pinkas-Kramarski, Tel Aviv University.*

## References:

1. M. Zayoud, V. Marcu-Malina, E. Vax, J. Jacob-Hirsch, G. Elad-Sfadia, I. Barshack, Y. Kloog, I. Goldstein, Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. *Frontiers in immunology* **8**, 799 (2017)
2. M. Zayoud, E. Vax, G. E. Sfadia, Y. Kloog, I. Goldstein, Farnesylthiosalicylic acid reduces disease severity in the collagen type-II induced arthritis mouse model by inhibiting Ras Signaling in pathogenic T cells. *The Journal of Immunology* **198**, 224.227-224.227 (2017)
3. M. Zayoud, E. Vax, G. E. Sfadia, V. Marcu-Malina, Y. Kloog, I. Goldstein, FRI0082 Ras signaling inhibitors attenuate arthritis in animal models of rheumatoid arthritis by down modulating the pathogenic th17 cell response. *Annals of the Rheumatic Diseases* **76**, 508-509 (2017)10.1136/annrheumdis-2017-eular.1083).
4. A. Bendele, J. McComb, T. Gould, T. McAbee, G. Sennello, E. Chlipala, M. Guy, Animal models of arthritis: relevance to human disease. *Toxicol Pathol* **27**, 134-142 (1999); published online EpubJan-Feb (
5. E. Aizman, A. Mor, J. George, Y. Kloog, Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells. *Eur J Pharmacol* **643**, 139-144 (2010); published online EpubSep 15 (
6. P. M. Cobelens, C. J. Heijnen, E. E. Nieuwenhuis, P. P. Kramer, R. van der Zee, W. van Eden, A. Kavelaars, Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. *Arthritis Rheum* **43**, 2694-2702 (2000); published online EpubDec (
7. D. D. Brand, K. A. Latham, E. F. Rosloniec, Collagen-induced arthritis. *Nat. Protocols* **2**, 1269-1275 (2007); published online Epub05//print (
8. K. A. Kuhn, L. Kulik, B. Tomooka, K. J. Braschler, W. P. Arend, W. H. Robinson, V. M. Holers, Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. *The Journal of Clinical Investigation* **116**, 961-973 (2006); published online Epub04/03/ (10.1172/JCI25422).
9. C. L. Langrish, Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, D. J. Cua, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* **201**, 233-240 (2005); published online EpubJan 17 (10.1084/jem.20041257).
10. M. I. Koenders, J. K. Kolls, B. Oppers-Walgreen, L. van den Bersselaar, L. A. Joosten, J. R. Schurr, P. Schwarzenberger, W. B. van den Berg, E. Lubberts, Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. *Arthritis Rheum* **52**, 3239-3247 (2005); published online EpubOct (10.1002/art.21342).
11. D. M. Roeleveld, M. I. Koenders, The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. *Cytokine* **74**, 101-107 (2015); published online Epub2015/07/01/ (<https://doi.org/10.1016/j.cyto.2014.10.006>).
12. L. F. da Rocha, Jr., A. L. Duarte, A. T. Dantas, H. A. Mariz, R. Pitta Ida, S. L. Galdino, M. G. Pitta, Increased serum interleukin 22 in patients with rheumatoid arthritis and


- correlation with disease activity. *J Rheumatol* **39**, 1320-1325 (2012); published online EpubJul (10.3899/jrheum.111027).
13. R. J. Marijnissen, M. I. Koenders, R. L. Smeets, M. H. T. Stappers, C. Nickerson-Nutter, L. A. B. Joosten, A. M. H. Boots, W. B. van den Berg, Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. *Arthritis & Rheumatism* **63**, 2939-2948 (2011)10.1002/art.30469).
  14. M. A. Pineda, D. T. Rodgers, L. Al-Riyami, W. Harnett, M. M. Harnett, ES-62 Protects Against Collagen-Induced Arthritis by Resetting Interleukin-22 Toward Resolution of Inflammation in the Joints. *Arthritis & Rheumatology* **66**, 1492-1503 (2014)10.1002/art.38392).
  15. L. G. Pinto, J. Talbot, R. S. Peres, R. F. Franca, S. H. Ferreira, B. Ryffel, J. C. F. Aves-Filho, F. Figueiredo, T. M. Cunha, F. Q. Cunha, Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1 $\beta$  production. *Arthritis Research & Therapy* **17**, 235 (2015)10.1186/s13075-015-0759-2).
  16. M. Noack, P. Miossec, Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. *Autoimmun Rev* **13**, 668-677 (2014); published online EpubJun (10.1016/j.autrev.2013.12.004).
  17. E. Lubberts, The IL-23-IL-17 axis in inflammatory arthritis. *Nat Rev Rheumatol* **11**, 562 (2015); published online EpubOct (10.1038/nrrheum.2015.128).

**Figure 1**




**Figure 1: Prophylactic treatment with FTS, F-FTS and MTX reduces the severity of collagen-induced arthritis (CIA).** 8-12 week-old DBA/1 male mice were given an initial injection of CFA/collagen type-2 (CII) on day 0, and arthritis was induced with a second booster injection of IFA/CII on day +21. Mice in the experimental arms (n=6 per group) were treated starting day +18 with daily FTS (100mg/kg), daily F-FTS (60mg/kg), weekly i.p injection of MTX (1 mg/kg), or 0.5% CMC vehicle solution (control treatment). **(A)** CIA severity was graded by a validated Clinical score (0-16 scale), starting from day +30 just prior to clinical arthritis onset. **(B)** Bar graphs depict mean value AUC  $\pm$  S.D. for the clinical CIA disease scores from days post immunization (DPI) +30 to +45, and a representative study of three independent experiments done is depicted (n=8 mice per treatment group). Inset shows the results of the statistical analysis of the differences in area under the curve (AUC) values for the different treatment arms. Statistical analysis was performed by one-way ANOVA with Bonferroni's post hoc multiple comparison test, using the Prism V.5.02 software (GraphPad Software, Inc).

**Figure 2**




**Figure 2. Prophylactic treatment with FTS significantly reduces the severity of CIA.** Disease was induced in 8-12-week-old DBA/1 male mice as detailed in the first figure legend. Mice in the experimental arms (n=8 per group) were treated semi-prophylactically, starting from day +18, with either oral FTS (100 mg/kg) or 0.5% CMC vehicle solution. **(A)** Clinical score of CIA severity was graded daily starting from day +30. **(B)** Bar graphs depict mean value  $\pm$  S.D of the calculated AUC, for CIA clinical disease scores from DPI +30 to +45 for FTS and CMC treatments (pooled data). One representative study out of 4 independent experiments is depicted. Statistical significance was calculated by the Student's t test ( $***P \leq 0.0001$ , by Student's t-test).

**Figure 3**



**Figure 3: Histopathological assessment of ankles of arthritic mice at study termination.** CIA was induced in 8-12-week-old DBA/1 male mice as detailed above. Mice in the experimental arms (n=8 per group) were treated semi-prophylactically, starting from day +18, with either oral FTS (100 mg/kg) or control CMC vehicle solution (0.5%). The tibiotarsal (ankle) joint was transected at the level of the medial and lateral malleolus for the Histopathological assessment. Ankle joints were collected into 4% paraformaldehyde, for at least 24 hours, and then placed in a decalcifier solution. Next, the joints were transected in the longitudinal plane and processed for paraffin embedding, sectioned and stained with hematoxylin & eosin. (A) Shown are representative images out of 3 experiments performed. Scale bars = 200  $\mu$ m. (B) Bar graphs depict the mean ( $\pm$  S.D) for the histological scores (1-5 scale), with separate scores for inflammation, pannus formation and bone resorption. The statistical significance of differences in scores for FTS vs. CMC therapy was calculated by Student's t-test (\* $P \leq 0.05$ ).


**Figure 4**



**Figure 4. FTS therapy reduces the levels of pathogenic anti-collagen antibodies and ACPA as well as inhibits the production of pro-inflammatory cytokines in CIA.** Sera from mice treated with FTS or CMC were collected at day 33 or 48 post immunization, and analyzed (A) by commercial ELISA kits for the level of circulating anti-collagen II (CII) antibodies. The data are presented as optical density (OD) at 450 nm. Bars represent mean  $\pm$  S.E.M of triplicates ( $P < 0.001$  for all individual active treatment arms vs. CMC, by *t*-test). (B) The sera collected from the mice were also serially diluted and analyzed for anti-citrullinated peptide antibodies (ACPA) by ready-made commercial ELISA kits. (C) Sera from counterpart mice were obtained at day +33 post immunization and analyzed for IL-17A and IL-6 levels by ready-made ELISA kits. Bars represent mean  $\pm$  S.D of triplicates from a representative experiment out of 2 performed ( $P < 0.001$  for all individual active treatment arms vs. CMC, by Student's *t*-test).




**Figure 5**




**Figure 5. Effects of FTS therapy on major splenic lymphocytic populations.** At study end (day +45), single cell suspension of spleens and LNs from the various groups of treated mice were analyzed by flow cytometry for CD3+ CD4+, and CD8+ T cell frequencies. **(A and B)** Representative FACS bivariate pseudo color dot plots of T cells (CD3+) and B cells (CD45R+) events, and bar graphs with pooled data from all mice studied (n = 6 per group) - respectively. Bars represent the mean percentage of the indicated cell population  $\pm$  S.D. **(C and D)** Representative FACS bivariate pseudo color dot plots of CD8+ cytotoxic T cells and CD4+ TH cells, and bar graphs with pooled data from all mice studied - respectively. Shown is a representative study out of 3 performed.

**Figure 6**




**Figure 6.** Analysis of the immunomodulatory effect of FTS therapy on IL-17A/IL-22 producing TH17 cells in CIA. At study end (day +45), single cell suspension of spleens and LNs from the various groups of treated mice were prepared, activated with Cell Stimulation Cocktail reagent, and then analyzed by flow cytometry for intracellular cytokine production. **(A)** Representative flow cytometry plots of intracellular staining of CD4<sup>+</sup> T cells for IL-17A and IL-22 cytokines production. **(B)** Bars represent the mean percentage ( $\pm$  S.D) of the indicated TH17-subsets in spleens of the various mice groups (n=6 per group). \*\*\* $P \leq 0.001$ , by the Student's t-test.

Figure 7



**Figure 7. FTS therapy mediates significant inhibition of the T cell recall response to CII.** 8-12-week-old DBA/1 male mice were immunized with CFA/type II collagen on day 0 and treated from Day +1 of the study with oral FTS or CMC vehicle for 10 days. Single-cell suspensions of splenocytes were prepared by mechanical disaggregation. Splenocytes were labeled with CFSE and stimulated *in vitro* with heat denatured bovine CII or control medium, and then cultured for additional 96 hours. (A) Cells were harvested and stained with anti-mouse CD3 and CD4 mAbs. And cells were analyzed for CII-specific proliferation of CD3+CD4+ T cells by flow cytometry (green for medium and red for CII). (B) In parallel, supernatants were collected and the levels of IL-6, IL-22 and IL-17a were determined by commercial ELISA kits. Bars represent mean  $\pm$  S.D. of triplicates from a representative experiment, and red bars represent CII stimulated cultures while green bars represent medium control cultures. Data were analyzed for statistical significance t-test for FTS treatment compared to CMC control treatment. Values of  $P < 0.001$ ,  $P < 0.01$ , and  $P < 0.05$  were marked by three, two and one asterisks, respectively.

Figure 8



**Figure 8. FTS inhibits T cell proliferation and IL-22 plus IL-17 production following in vitro polyclonal stimulation.** CD4+ T cells were purified by negative selection from spleens of naïve 8-12-week-old DBA/1 male mice using magnetic cell separation technology (MACS, Miltenyi Biotec, Germany). CD4+ T cells were labeled with CFSE and activated by plate-bound anti-CD3 and soluble anti- CD28 in fully supplemented RPMI for 3 days. During T cell activation cells were treated with the indicated concentrations FTS dissolved in DMSO. **(A and B)** Representative and Statistical analysis proliferated CD4+ T-cells with different dose of FTS. One representative of two independent experiments is shown **(C)** At the end of culture, the supernatants were collected and tested for secreted IL-17A and IL-22 by ELISA.

**What opportunities for training and professional development has the project provided?**

*If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.*

Training activity for Ph.D. graduate student Morad Zayoud M.D. included one-on-one work with Dr. Goldstein (mentor) and participation in conferences, workshops and seminars, as detailed:

1. New Horizons in Immune Dynamics 2017 (July 18, Weizmann Institute, Israel).
2. IMMUNOLOGY™ 2017 meeting (May 12-16, Washington, DC) of the "The American Association of Immunologists".
3. The annual meeting of the Israel society of Rheumatology 2017 (April 27-28, Israel).

All other members of the project's team participate in regular lab/project team internal seminars supervised by the partnering PIs, and designed to advance their professional research / academic skills.

**How were the results disseminated to communities of interest?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.*

*“Nothing to Report.”*

**What do you plan to do during the next reporting period to accomplish the goals?**

*If this is the final report, state “Nothing to Report.”*

*Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.*

As stated in our most current revised approved SOW our plans for the next reporting period - 12 mo. extension period at no cost - of the award are as follows:

(i) To accomplish all the aims detailed in the approved revised Major Task 2, we next plan to gain a more comprehensive insight into the "molecular mechanism" that mediate the therapeutic action of small molecule Ras-inhibitors in the mouse CIA model. Thus, we have designed experiments to analyze the changes in gene expression (transcriptome) mediated by in vivo FTS therapy. LN/spleen derived CD4<sup>+</sup> T cells from mice immunized with CII and treated with FTS or vehicle CMC will be re-challenge with CII antigens. 72 hrs later the cells will be lysed and total high quality RNA will be obtained for downstream analysis. Global Gene expression will be determined using the GeneChip® Mouse Gene Array System (Affymetrix, Inc.), according to the manufacturer's instructions. Thereafter, we will perform Gene Set Enrichment Analysis (GSEA) to compute the overlaps between our gene list and all gene sets in the major collections of the Molecular Signatures Database (MSigDB; developed at the Broad Institute of MIT and Harvard). This and other bioinformatics analyses of the transcriptomics data, indeed will allow us to gain further insight into the biology behind the effect of FTS in the CIA model and compare it to our relevant results in the AIA.

(ii) To complete the aims detailed in Major Task 4 and gain further understanding of the, effects of FTS and F-FTS on various T cell-signaling events following TCR stimulation, and other biologically relevant molecular pathways. Thus we will study the effects of FTS and its derivative F-FTS on a wide range of molecular pathways in mouse T cells following in vitro polyclonal TCR stimulation with anti-CD3/CD28 mAbs, as follows: (a) MAPKKK (Raf)/MAPKK (MEK1/2)/MAPK (ERK1/2) pathway; (b) PI3K/Akt pathway; and (c) the RAL pathway. We will also further test the effects of Ras inhibitors on the production of selected pro-inflammatory and regulatory cytokines relevant to the pathogenesis of RA. Lastly, we will assess the effects of Ras inhibitors on the expression and/or phosphorylation of various transcription factors vital for TH cell polarization.

(iii) To publish a co-authored comprehensive peer-reviewed research paper, describing the mechanisms (cellular and molecular) that control/mediate the immunomodulatory effects of small molecule Ras inhibitors in the AIA and CIA animal models of RA, including mechanistic data derived from the in vitro work in Task 4. We plan to complete the experiments described above and analyze all our data by month 42 of the project. This will enable us to write the manuscript and submit it for publication in a relevant International Scientific Journal.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

**What was the impact on the development of the principal discipline(s) of the project?**

*If there is nothing significant to report during this reporting period, state "Nothing to Report." Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge,*

*theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).*

The results and achievements of our research project have the potential to make significant contributions to both basic immunology and the clinical care of rheumatoid arthritis (RA).

*Short-term impact:* The results of this project improve our insight on the role of Ras signaling (and its blockade) on the T cell response in preclinical animal models of RA. Our in vivo results show that Ras signaling is important for the induction of T helper (TH) 17-type effector responses, while its blockade inhibits this autoimmune response and enhances peripheral immune tolerance by increasing the ratio of FoxP3+ regulatory T cells (Treg).

*Long-term impact:* The results of this project strongly imply that FTS (Salirasib) and/or its more potent analogue, F-FTS, have the potential to become important novel targeted synthetic anti-rheumatic drug. Obviously, the development of FTS into an effective (and cheaper) oral drug for RA may ultimately impact the clinical care of RA patients. The prevalence of RA in adult Americans is estimated at ~1.5 million. Regarding the prevalence of RA in veterans, available epidemiological data indicates that ~1% of patients seen each year in outpatient settings have a diagnosis of RA. FTS (Salirasib) is the only available successful Ras inhibitor that reached Phase II clinical trials, and consequently received an orphan drug designation by the FDA and EMA for the treatment of pancreatic cancer. Our results signify that its introduction into the field of rheumatology should be a remarkable

#### **What was the impact on other disciplines?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.” Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.*

“Nothing to Report.”

#### **What was the impact on technology transfer?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.” Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:*

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

“Nothing to Report.”

#### **What was the impact on society beyond science and technology?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*



*Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:*

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

“Nothing to Report.”

- 5. CHANGES/PROBLEMS:** The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

**Changes in approach and reasons for change**

*Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.*

“Nothing to Report.”

**Actual or anticipated problems or delays and actions or plans to resolve them**

*Describe problems or delays encountered during the reporting period and actions or plans to resolve them.*

As stated in the 2nd year Annual Technical Report and SOW our research aims for the third year (CY17) of the award were as follows:

- To validate in the collagen induced arthritis (CIA) mouse model the prophylactic and/or therapeutic effects of FTS and the FTS derivative, F-FTS (Task 2).
- To analyze the in vitro effects of FTS and its derivative F-FTS on various T cell-signaling events following TCR stimulation.

Unfortunately, there has been an unexpected delay with ACURO approval of our recent animal use protocol due to a lengthy review time. The animal protocol PR130028.05 entitled, "Studying the Immunomodulatory Effects of Ras-Inhibitors in the Collagen Induced Arthritis Mouse Model," IACUC protocol number 04-17-005 was therefore approved by the USAMRMC Animal Care and Use Review Office (ACURO), only at the end of APRIL 2017. Thus, our animal experiments, as described above (aim i) could be continued only after the 1st of May 2017. Thus. We estimated a 9-12 months delay in finalizing the animal studies related to Major Tasks 2 and 4 and completing Milestone #2, and requested a no-cost extension of 12 months of the award performance period. The request for extension and the revised SOW were approved on Aug. 2017.

**Changes that had a significant impact on expenditures**

*Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.*

“Nothing to Report.”

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

*Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.*

**Significant changes in use or care of human subjects**

“Nothing to Report.”

**Significant changes in use or care of vertebrate animals**

“Nothing to Report.”

**Significant changes in use of biohazards and/or select agents**

“Nothing to Report.”

**6. PRODUCTS:** List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

**Journal publications.** *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted,*

*awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

**Journal publications (peer-reviewed research papers):**

M. Zayoud, V. Marcu-Malina, E. Vax, J. Jacob-Hirsch, G. Elad-Sfadia, I. Barshack, Y. Kloog, I. Goldstein, Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. *Frontiers in immunology* 8, 799 (2017) published on line July 2017. (04/18/17 received; 06/23/17 accepted)

***Acknowledgement of federal support: yes.***

**Other publications, conference papers and presentations.** *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (\*) if presentation produced a manuscript.*

**Conference papers:**

**1.** Morad Zayoud, Einva Vax, Galit Elad Sfadia, Yoel Kloog and Itamar Goldstein. Farnesylthiosalicylic acid reduces disease severity in the collagen type-II induced arthritis mouse model by inhibiting Ras Signaling in pathogenic T cells. *The Journal of Immunology* 198(1 Supplement):224.227-224.227. Published online May 1, 2017.

This abstract, summarizing our major accomplishments in this research award, was selected for publication and Poster presentation in the prestigious international **IMMUNOLOGY™ 2017** meeting (May 12-16, Washington, DC) of the "The American Association of Immunologists". This conference is the largest annual gathering of immunologists worldwide.

**2.** M. Zayoud, E. Vax, G. Elad Sfadia, V. Marcu-Malina, Y. Kloog, I. Goldstein. RAS SIGNALING INHIBITION ATTENUATES ARTHRITIS IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY DOWN MODULATING THE PATHOGENIC TH17 CELL RESPONSE. *Annals of Rheumatic Diseases* (Supplement 1) 2017. DOI: 10.1136/annrheumdis-2017-eular.2843

This abstract was accepted for publication and poster display/presentation in The European League against Rheumatism Congress, **EULAR 2017** (14-17 June, Madrid, Spain). This presentation summarized our findings and accomplishments in the AIA and CIA models of RA with a translational emphasis. The abstract was also selected for presentation, in a GUIDED POSTER TOUR: "New drivers in RA and SPA pathophysiology" attended by scientists from academic institutions and industry, as well as physician/rheumatologists.

- **Website(s) or other Internet site(s)**

*List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.*

“Nothing to Report.”

- **Technologies or techniques**

*Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.*

“Nothing to Report.”

- **Inventions, patent applications, and/or licenses**

*Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.*

“Nothing to Report.”

- **Other Products**

*Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:*

- *data or databases;*
- *models;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *and other.*

“Nothing to Report.”

## **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

### **What individuals have worked on the project?**

*Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.*

**Name:** **Itamar Goldstein**  
**Project Role:** Initiating Primary Investigator  
**Researcher Identifier (e.g. ORCID ID):** 0000-0001-5393-186X  
**Nearest person month worked:** 2  
**Contribution to Project:**  
Dr. Goldstein has supervised all aspects of the project, including mentorship of PhD graduate students and co-authoring of all manuscripts and other publications.

**Name:** **Morad Zayoud**  
**Project Role:** Ph.D. Graduate Student  
**Researcher Identifier (e.g. ORCID ID):** N/A  
**Nearest person month worked:** 12  
**Contribution to Project:**  
Dr. Zayoud has performed the experiments in the AIA and CIA models and analyzed relevant data, and co-authored the Manuscript and other publications in partial fulfillment of the requirements for his Ph.D. degree from Tel Aviv University.

**Name:** **Einav Vax**  
**Project Role:** Research Associate  
**Researcher Identifier (e.g. ORCID ID):** N/A  
**Nearest person month worked:** 6  
**Contribution to Project:**  
Einav has managed all technical aspects of the project, and participated in the majority of the experiments in the AIA and CIA models.

**Name:** **Ronit Pinkas-Kramarski**  
**Project Role:** Partnering Primary Investigator  
**Researcher Identifier (e.g. ORCID ID):** 0000-0002-1000-369X  
**Nearest person month worked:** 1  
**Contribution to Project:**  
Prof. Pinkas-Kramarski co-supervised all aspects of the project and directly supervised Galit Elad Sfadia and Itzhak Ben Moshe.

**Name:** **Galit Elad Sfadia**  
**Project Role:** Research Associate  
**Researcher Identifier (e.g. ORCID ID):** N/A  
**Nearest person month worked:** 6  
**Contribution to Project:**  
Galit has participated in the experiments of the AIA and CIA models and contributed to the analysis of relevant data.

**Name:** **Itzhak Ben Moshe**  
**Project Role:** Technical Assistant  
**Researcher Identifier (e.g. ORCID ID):** N/A  
**Nearest person month worked:** 6  
**Contribution to Project:**  
Itzhak has participated in all the in experiments in animal models and helped collect the data.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.*

“Nothing to Report.”

**What other organizations were involved as partners?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.*

“Nothing to Report.”

## **8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:** For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

**QUAD CHARTS:** If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.

- 9. APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.



# Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis *via* Targeting Pathogenic Antigen-Specific Th17-Type Cells

Morad Zayoud<sup>1,2,3</sup>, Victoria Marcu-Malina<sup>1,3</sup>, Einav Vax<sup>1,3</sup>, Jasmine Jacob-Hirsch<sup>1</sup>, Galit Elad-Sfadia<sup>4</sup>, Iris Barshack<sup>5</sup>, Yoel Kloog<sup>4</sup> and Itamar Goldstein<sup>1,2,3\*</sup>

<sup>1</sup> Sheba Cancer Research Center, Chaim Sheba Academic Medical Center, Ramat Gan, Israel, <sup>2</sup> Rheumatology Unit, Chaim Sheba Academic Medical Center, Ramat Gan, Israel, <sup>3</sup> Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, <sup>4</sup> Department of Neurobiology, The George S. Wise Faculty of Life Sciences & Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel, <sup>5</sup> Institute of Pathology, Chaim Sheba Academic Medical Center, Ramat Gan, Israel

## OPEN ACCESS

### Edited by:

Massimo Gadina,  
National Institute of Arthritis and  
Musculoskeletal and Skin  
Diseases, United States

### Reviewed by:

Laura Mandik-Nayak,  
Lankenau Institute for Medical  
Research, United States  
Franz Rödel,  
University Hospital Frankfurt,  
Germany

### \*Correspondence:

Itamar Goldstein  
itamar.goldstein@sheba.health.gov.il

### Specialty section:

This article was submitted  
to Inflammation,  
a section of the journal  
Frontiers in Immunology

**Received:** 18 April 2017

**Accepted:** 23 June 2017

**Published:** 07 July 2017

### Citation:

Zayoud M, Marcu-Malina V, Vax E,  
Jacob-Hirsch J, Elad-Sfadia G,  
Barshack I, Kloog Y and Goldstein I  
(2017) Ras Signaling Inhibitors  
Attenuate Disease in Adjuvant-  
Induced Arthritis *via* Targeting  
Pathogenic Antigen-Specific  
Th17-Type Cells.  
Front. Immunol. 8:799.  
doi: 10.3389/fimmu.2017.00799

The Ras family of GTPases plays an important role in signaling nodes downstream to T cell receptor and CD28 activation, potentially lowering the threshold for T-cell receptor activation by autoantigens. Somatic mutation in *NRAS* or *KRAS* may cause a rare autoimmune disorder coupled with abnormal expansion of lymphocytes. T cells from rheumatoid arthritis (RA) patients show excessive activation of Ras/MEK/ERK pathway. The small molecule farnesylthiosalicylic acid (FTS) interferes with the interaction between Ras GTPases and their prenyl-binding chaperones to inhibit proper plasma membrane localization. In the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA). We show that AIA severity was significantly reduced by oral FTS and F-FTS treatment compared to vehicle control treatment. FTS was as effective as the mainstay anti-rheumatic drug methotrexate, and combining the two drugs significantly increased efficacy compared to each drug alone. We also discovered that FTS therapy inhibited both the CFA-driven *in vivo* induction of Th17 and IL-17/IFN- $\gamma$  producing “double positive” as well as the upregulation of serum levels of the Th17-associated cytokines IL-17A and IL-22. By gene microarray analysis of effector CD4<sup>+</sup> T cells from CFA-immunized rats, re-stimulated *in vitro* with the mycobacterium tuberculosis heat-shock protein 65 (Bhsp65), we determined that FTS abrogated the Bhsp65-induced transcription of a large list of genes (e.g., *Il17a/f*, *Il22*, *Ilfng*, *Csf2*, *Lta*, and *Il1a*). The functional enrichment bioinformatics analysis showed significant overlap with predefined gene sets related to inflammation, immune system processes and autoimmunity. In conclusion, FTS and F-FTS display broad immunomodulatory effects in AIA with inhibition of the Th17-type response to a dominant arthritogenic antigen. Hence, targeting Ras signal-transduction cascade is a potential novel therapeutic approach for RA.

**Keywords:** Ras GTPases, rheumatoid arthritis, farnesylthiosalicylic acid, adjuvant induced arthritis, T-helper cells

## INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disorder that principally affects synovial joints (1). Th17 cells have been postulated to play a key role in the pathogenesis of several autoimmune diseases (2) and in animal models of human autoimmune diseases including autoimmune colitis (3), experimental autoimmune encephalomyelitis (4), collagen-induced arthritis (5), and rat adjuvant-induced arthritis (6).

Ras-GTPases are molecular switches that regulate key cellular processes, such as proliferation, differentiation, apoptosis, and motility. In T cells, Ras-family GTPases (e.g., K/N-Ras) are crucial for proper T-cell receptor (TCR)-dependent activation following antigen recognition. Defective activation of Ras/Raf/MEK/ERK1/2 cascade has been associated with T cell anergy, and accordingly increased expression of active Ras was shown to reverse anergy and to restore IL-2 production (7–9). Moreover, T cells from patients with RA have been found to express significantly higher levels of K-Ras and its downstream effector B-Raf that mediate the increased levels of phospho-ERK1/2 observed in RA patients' T cells (10, 11). Importantly, over expression of K-Ras in CD4<sup>+</sup> T cells from healthy donors enabled the induction of autoreactive T cells that reacted citrullinated vimentin-derived peptides, postulated to be a pathogenic autoantigen in RA. Thus, hyperactivity of the Ras signal transduction cascade has been postulated to increase TCR-sensitivity to low-affinity antigens, including many clinically relevant autoantigens (10, 11). Interestingly, previous reports suggest that inner plasma membrane (PM)-anchored Ras proteins can transfer from antigen-presenting B cells to T cells both through the immunological synapse and through actin supported long-range PM extensions termed tunneling nanotubes. These findings further support the importance of Ras GTPases in immunity, by showing that active Ras-GTPase signals can spread between immune cells (12, 13) and even from cancer cells expressing oncogenic Ras to T cells (14).

Activating mutations in the proto-oncogenes *KRAS* and *NRAS* are frequent in human cancers (15, 16). This has led to ongoing efforts to develop drugs that target Ras signaling (16–20). To be active, Ras GTPases have to associate with membranes, and hence they require several posttranslational modifications in their carboxy-terminal domain, such as the addition of the hydrophobic farnesyl isoprenoid molecule to Cysteine 186 that is conserved in all Ras family members (16, 21–23). Based on an innovative concept, Kloog and colleagues (24, 25) discovered a potent non-toxic inhibitor of active (GTP-bound) Ras proteins, the small molecule farnesylthiosalicylic acid (FTS/Salirasib).

In recent years, it has been discovered that following posttranscriptional processing Ras proteins interact with prenyl-binding chaperones (26–29). These chaperones with prenyl-binding hydrophobic pockets are vital for proper PM localization and effective downstream Ras signaling (30). In agreement with this concept, it was found that FTS, by competing for Ras-chaperon interactions, effectively dislodges the oncogenic Ras proteins from the PM and inhibits Ras mediated oncogenesis (31–33).

The central role of Ras signaling in T cells strongly suggests that targeting Ras might be an effective therapeutic approach for

this disease. Over the past decade the effects of FTS and related analogs have been extensively studied in multiple pre-clinical animal models of autoimmune. For example, FTS can attenuate disease manifestations in experimental autoimmune encephalomyelitis (34, 35), Type 1 diabetes in NOD mice (36), experimental colitis (37), and other autoimmune diseases such as systemic lupus erythematosus (38). Preliminary studies by Aizman et al. (39) in the adjuvant-induced arthritis (AIA) model in rats suggest that prophylactic treatment with FTS may attenuate the clinical score of the disease; however, the biology behind the effect of FTS was not comprehensively elucidated. AIA is an experimental animal model of polyarthritis, which can be induced in inbred Lewis rats by immunization with Complete Freund's adjuvant containing *Mycobacterium tuberculosis* (Mtb). Importantly, mycobacterial heat-shock protein 65 (Bhsp65) reactive T cells have been implicated in the pathogenesis of AIA. The AIA model and human RA have many overlapping characteristics, such as genetic susceptibility, T cell dependence, and pathogenic contribution of synovial CD4<sup>+</sup> cells. Therefore, this model has been extensively employed for preclinical testing of numerous anti-arthritic agents, including biologics used for latest therapy in RA (40, 41). As previous studies imply that the main mechanism of action of FTS is down modulation of the T cell response (36), and the major role of T cells in AIA pathogenesis (42), we chose this pre-clinical model to assess the therapeutic potential of FTS in human RA.

Here, we provide a comprehensive insight into the molecular mechanisms that mediate the therapeutic action of small molecule Ras-inhibitors in AIA. Moreover, we determined that prophylactic treatment with FTS as an add-on to methotrexate (MTX) inhibits almost completely the development of AIA by all clinical and immunological/molecular outcome measures.

## MATERIALS AND METHODS

### Animals

Lewis rats obtained from Harlan Biotech (Rehovot, Israel). All rats were subjected to regular health status controls. Male rat, 8 weeks of age were used for experiments. All animal experiments were conducted in accordance with relevant laws of the state of Israel and guidelines of the Tel Aviv University and approved by the Institutional Animal Care and Use Committee (Approval # L-14-018).

### Arthritis Induction and Drug Administration

To induce AIA, the rats have been injected intradermal (i.d.) at the base of the tail with 100 µl CFA produced by suspending heat-killed *M. tuberculosis* (Difco) in mineral oil at 10 mg/ml. For drug administration, on day +1 after AIA induction, the rats were randomly divided into four groups. Rats in the first group were treated daily (starting on day 1 after AIA induction) with oral (intragastric) FTS (100 mg/kg). Rats in the second group (control) received oral vehicle [0.5% carboxy methyl cellulose (CMC)] daily. Rats in the third group were treated with i.p MTX (0.5 mg/kg) on days 3, 10, and 17 after AIA induction.



Rats in the fourth group (FTS + MTX) were treated daily (starting on day 1 after AIA induction) with oral (intragastric) FTS (100 mg/kg) as well with i.p MTX (0.5 mg/kg) on days 3, 10, and 17 after AIA induction. 20 days after the experiment has been terminated. As negative control, we used naïve healthy rats without any treatment. For determining the clinical scores, each paw is scored on a scale of 0–4 for the degree of swelling, erythema, and deformity of the joints with a maximum total score of 16 (43).

## Lymphocyte Isolation, Intracellular Cytokine Staining, and Flow Cytometric Analysis

Single-cell suspensions of splenocytes and inguinal lymph nodes (LN) were prepared by mechanical disaggregation followed by lysis of red blood cells with a commercial ammonium chloride buffer (Gibco, Thermo Fisher Scientific, Inc.). T cells were stained as indicated with the following anti-rat CD monoclonal antibodies (mAbs): CD3-PE, CD4-FITC, CD8-PE-Cy7, and CD25-PE (all from eBioscience). For intracellular cytokine staining, freshly isolated lymphocytes were activated for 5 h *ex vivo* in RPMI medium with 1× Cell Stimulation Cocktail in the presence of a commercial Protein Transport Inhibitor Cocktail according to the manufacturer's protocol (eBioscience). Thereafter, cells were surface-stained with anti-CD4-FITC, washed, fixed, and permeabilized using BD Cytofix/Cytoperm™ kit, per manufacturer's instructions (BD Biosciences). Intracellular staining was performed with anti-rat IL-17A-PE and IFN- $\gamma$ -APC (both mAbs from eBioscience) and the BD Perm/Wash™ Buffer. For Treg cells staining, the cells were surface stained for CD4 and CD25, washed, fixed, and permeabilized using the Foxp3 Staining Buffer Set, and then immunostained with anti-mouse/rat Foxp3-APC mAbs (all reagents from eBioscience). Samples were acquired using a FACSAria flow cytometer (BD Bioscience) and further analyzed using the FlowJo v10 software (TreeStar, Inc.).

## Measurement of Cytokines and CRP in Serum and Cell Culture Supernatant by ELISA

The serum levels of the inflammatory mediator CRP were determined by the rat specific CRP Elisa Kit (R&D Systems, Inc.). The levels of cytokines IL-17A and IL-22 from the collected rats sera and in cell culture supernatant were determined by rat specific IL-17A (homodimer) ELISA Ready-SET-Go kit (eBioscience) and by the rat IL-22 ELISA Kit (R&D Systems, Inc.), respectively.

## Processing and Evaluation of Joint Histology

At study termination, the tibiotarsal joint was transected at the level of the medial and lateral malleolus for Histopathological Assessment. Ankle joints were then collected into 4% paraformaldehyde, for at least 24 h, and then placed in a decalcifier solution with 10% hydrochloric acid. When decalcification was completed, the ankle joint was transected in the longitudinal plane and joints

were processed for paraffin embedding, sectioned, and stained with hematoxylin and eosin. Tissue section slides of arthritic ankles were examined by an experienced pathologist, blinded to the animal treatment protocol, and scored for inflammation and bone resorption on a scale of 0–5, as previously described (44).

## Antigen-Specific T Cell Activation and Cell Cultures

Freshly isolated splenocytes were plated in 24 well plates at  $2 \times 10^6$  and re-challenged *in vitro* with Bhsp65 (5  $\mu$ g/ml) or control vehicle, and cultured for additional 72 h in complete RPMI medium supplemented with 10% FCS. At culture termination, we first collected the supernatants for relevant analyses and then harvested the cells and isolated the CD4<sup>+</sup> T cell population using Rat CD4 MicroBeads and the MACS cell separation platform (Miltenyi Biotec, Germany), according to the manufacturer's instructions.

## GeneChip Microarray Analysis

The purified CD4<sup>+</sup> T cell was lysed with the TRIzol® Reagent (Invitrogen, Carlsbad, CA, USA), and total RNA was purified using the Direct-zol™ RNA Kit (Zymo Research Corporation, Irvine, CA, USA) for subsequent downstream analysis. Gene expression was determined using the GeneChip® Rat Gene 2.0 ST Array System (Affymetrix, Inc.), according to the manufacturer's instructions. The 2100 Bioanalyzer (Agilent Technologies) was used to determine RNA quality, and biotinylated target DNA was prepared from each suitable RNA sample according to the manufacturer's instructions. Gene level RMA sketch algorithm was used for crude data generation (Affymetrix Expression Console and Partek Genomics Suite 6.2). Genes were analyzed using unsupervised hierarchical cluster analysis (Spotfire DecisionSite for Functional Genomics; Somerville, MA, USA) to get a first assessment of the data, and filtered according to fold change calculations. For further functional bioinformatics analysis to discover molecular processes and biological pathways enriched in the experimental dataset, we used the Gene Set Enrichment Analysis (GSEA) software available online (<http://software.broadinstitute.org/gsea/msigdb/annotate.jsp>). The primary microarrays data from this research have been deposited in the NCBI Gene Expression Omnibus data repository under accession number GSE100280.

## Reverse Transcription and Real-time qPCR

Total RNA was extracted from CD4<sup>+</sup> cells using TRIzol® Reagent (Invitrogen, Thermo Fisher Scientific, Inc.), and total RNA was purified using Direct-zol™ RNA Kits (Zymo Research Corporation), followed by treatment with 1 U of RNase-free DNase (Roche). Reverse transcription reactions were performed on 1  $\mu$ g total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. The quantitative PCR (qPCR) analyses for the relative mRNA expression of Ccl20, Il22, Il17A, Il17E, and Csf2 (normalized to Actb) were performed with premade QuantiTect bioinformatically validated

primer sets (from Qiagen) and the SYBR Green Real-Time PCR Kit (Applied Biosystems) on an ABI Prism 7900 SDS Instrument (Applied Biosystems), as recommended by the manufacturers, in reactions containing 50–100 ng cDNA. All reactions were done in triplicates and relative mRNA quantities (RQ) were determined using the  $2^{-\Delta\Delta C_t}$  method.

## Statistical Analysis

Statistically significant differences between group means were determined either by the one-way ANOVA test with Bonferroni's *post hoc* multiple comparison test or the Student's *t*-test, as appropriate, using the Prism win V.5.02 software (GraphPad Software, Inc.).

## RESULTS

### FTS Treatment Attenuates Disease Severity in AIA

To determine whether treatment with FTS suppresses the clinical signs of AIA, we started daily treatment of rats from day +1 after immunization in the experimental arm with oral FTS (100 mg/kg). Control rats received oral solution of 0.5% CMC (vehicle). As a “positive control,” we treated a group of Lewis rats with weekly *i.p.* injection of the anti-rheumatic drug MTX (0.5 mg/kg). AIA progression and severity was scored on a clinical index of 0–16 (0–4 scale for each paw). In parallel, we also assessed arthritis severity and progression by successive caliper measurements of ankle joint diameter. We found that in the FTS treatment arm the arthritis was significantly attenuated ( $P < 0.001$ ) as compared to CMC vehicle treated rats by both clinical scoring and ankle joint diameter measurements (Figures 1A,B). The clinical effects of FTS, with respect to arthritis severity and joint swelling, were of similar magnitude to the effects of MTX. Moreover, we also discovered that treatment with FTS as an add-on to MTX provided a very strong protective effect such as that the combined treatment almost completely inhibited the development of clinically evident arthritis (Figure 1A) and ankle joint swelling (Figure 1B). To further evaluate the effects of FTS on arthritis development, we examined ankle joint sections stained with hematoxylin and eosin from the various treatment arms (Figure 1C). Ankles of rats treated with adjuvant were given scores of 0–5 for bone resorption and inflammation, as previously described (44). The histological joint tissue sections from 0.5% CMC vehicle treated rats showed extensive infiltration with mononuclear cells (inflammation scores ranging from 4 to 5,  $n = 5$ ), and significant bone destruction (bone resorption scores ranging from 4 to 5). In comparison, the sections from FTS treated rats showed less joint tissue infiltration by mononuclear cells (inflammation scores ranging from 2 to 3,  $n = 5$ ), and less destruction of trabecular and cortical bone in the distal tibia (bone resorption scores ranging from 2 to 3). Moreover, the tissue sections from rats treated with FTS as an add-on to MTX showed only mild joint tissue infiltration with mononuclear cells (inflammation scores ranging from 2 to 3) and only rare areas of trabecular or cortical bone resorption not readily apparent on low magnification (average bone resorption scores of  $\leq 2$ ).

### FTS Inhibits the Upregulation of Pathogenic Serum Cytokines and Relevant Biomarkers


To investigate the immunomodulatory effect of FTS on the response to immunization with mTb containing CFA, we analyzed the levels of the key Th17 cell cytokines, IL-17A and IL-22, in serum samples collected at day 14 of the experiment. We found that treatment with FTS or MTX alone significantly reduced ( $P < 0.001$ ) serum IL-17 levels compared to control CMC-treated arthritic rats (Figure 2A). Furthermore, combined treatment with FTS and MTX was extra potent in suppressing IL-17 upregulation, as compared to single agent therapy ( $P < 0.01$ ). As predicted CFA immunization also induced a strong upregulation of serum IL-22 as compared to naïve healthy unimmunized littermate rats. The IL-22 response observed in CMC treated rats was significantly inhibited by either FTS or MTX therapy ( $P < 0.001$ ) (Figure 2B). Interestingly, treatment with FTS alone or as an add-on to MTX had a more significant capacity to inhibit IL-22 production, as compared to MTX as a single agent ( $P < 0.01$  for FTS and FTS + MTX vs. MTX).

In parallel, we analyzed the levels of serum CRP, a typical acute phase reactant protein in humans and in the rat (45). As expected, CFA injection induced a substantial increase in CRP levels in control CMC treated rats compared to naïve healthy littermate rats. Next, we found that FTS, MTX, and FTS as an add-on to MTX treatments equally and significantly reduced the arthritis-associated upregulation of serum CRP levels at day 14 of the experiments (Figure 2C).

### Characterizing the Immunomodulatory Effects of FTS on the *In Vivo* T Cell Response

The use of this adjuvant model also offers an opportunity to study the pathological changes in a variety of tissues other than the joints. For example, the splenomegaly that develops as part of the systemic inflammation induced by CFA (40, 44). Thus, at study end, we could study the effects of the immunization and the various treatment protocols on the cellular immune response to CFA, principally analyzing by polychromatic flow cytometry the single cell suspension of spleens and peripheral blood samples for changes in CD4<sup>+</sup> and CD8<sup>+</sup> T cell percentages. Our results show that CFA immunization itself induced a significant decline ( $P < 0.05$ ) in the percentage of circulating CD3<sup>+</sup> T cells but not in splenic T cells. However, the various treatment regimens had only a marginal effect on the percentage of circulating and splenic CD3<sup>+</sup> T cells. Moreover, we found that the various treatments had no significant effects on CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells percentage both in the spleen and the blood at study end. Nevertheless, we observed a trend ( $P = 0.08$ ) for an increased CD4<sup>+</sup> to CD8<sup>+</sup> T cell ratio in the FTS therapy arm (Figures 3A–C).

As both IL-17<sup>+</sup> and IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> Th17-type cells have been shown to be instrumental for the pathogenesis of autoimmune responses (46), we analyzed the effects of FTS and other treatment protocols on the induction of IL-17 and IFN- $\gamma$  expressing T cells in arthritic rats spleens by intracellular cytokine staining.




**FIGURE 1** | Farnesylthiosalicylic acid (FTS) treatment reduces the severity of adjuvant-induced arthritis. Rats were immunized with CFA and then graded regularly for signs of arthritis by a clinical disease severity score **(A)**, and by caliper measurements of ankle joint diameter **(B)**. Rats in the experimental arms were treated starting day +1 with either oral FTS (100 mg/kg), 0.5% carboxymethyl cellulose (CMC) vehicle solution, weekly i.p injection of MTX (0.5 mg/kg), or FTS combined with MTX. Statistical analysis of the AUC of the effect of the various treatments on the clinical score **(A)** and ankle diameter **(B)** was done by one way ANOVA with *post hoc* Bonferroni's multiple comparison test. The results of the analysis are summarized in the table inset. One representative of three independent experiments is depicted (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , and \*\*\* $P \leq 0.001$ ). **(C)** Tibiotarsal (ankle) joint tissue sections were stained with H&E for histopathological assessment, and scored on a scale of 0–5 for inflammation and bone resorption. The bar graph represents the quantification and statistical analysis of histopathology of ankles of arthritic rats in the various treatment arms. Shown bars from >3 experiments performed with  $n = 8$  rats in each treatment arm.


Our data show that CFA immunization induced a significant induction of IL-17<sup>+</sup> (~20-fold increase;  $P < 0.001$ ) and of IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> Th17 cells ( $4.6 \pm 0.34$  vs.  $0.04 \pm 0.01$ ,  $P < 0.01$ ) compared to naive unimmunized rats. Moreover, FTS therapy alone as well as the other treatments all induced a significantly lower induction of pathogenic Th17 cells in the spleens of FTS treated rats compared to CMC vehicle treated arthritic rats  $P < 0.001$ . Interestingly, FTS as an add-on to MTX therapy induced a more significant reduction in the percentage of the highly pathogenic IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> T cells, as compared to either

drug alone  $P < 0.01$  (Figures 4A,B). Thus, the Th17 cell response data showed a positive and significant correlation with the clinical outcomes data of the various treatment protocols.

Next, we analyzed the effects of FTS and the different treatments on the induction of IFN- $\gamma$ <sup>+</sup> Th1 cells in the spleens. We found that, in contrast to the Th17 data, CFA immunization did not produce a significant increase in splenic Th1 cells percentage compared to naive unimmunized rats. Additionally, FTS therapy did not significantly reduce the induction of Th1 cells in the spleens of treated rats compared to CMC control arthritic rats.




**FIGURE 2 |** Farnesylthiosalicylic acid (FTS) treatment reduces serum Th17-cytokines and CRP levels during arthritis development. Sera from rats treated with carboxymethyl cellulose (CMC), FTS, FTS + MTX, or MTX was collected at Day 14 post adjuvant injection (day +3 from arthritis onset) and analyzed for (A) IL-17A, (B) IL-22, and (C) CRP levels by ELISA kits. Bars represent mean  $\pm$  SD of triplicates from a representative experiment out of three performed ( $n = 4$  rats analyzed per group). ND, not detectable. Statistical significance among groups was analyzed by the Student's *t*-test (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , and \*\*\* $P \leq 0.001$ ).



**FIGURE 3 |** Effects of farnesylthiosalicylic acid (FTS) therapy on splenic and peripheral blood T cell populations. At study termination, single cell suspension of spleens (A,B) and peripheral blood (C) from the various groups of treated rats ( $n = 8$  per group) were analyzed by flow cytometry for CD3<sup>+</sup> CD4<sup>+</sup>, and CD8<sup>+</sup> T cell frequencies. Samples were acquired on a FACSAria instrument (~50,000 single cell events per sample) and analyzed using the FlowJo software. The results shown represent a typical experiment out of >5 performed.





**FIGURE 4 | Continued**

Immunomodulatory effect of farnesylthiosalicylic acid (FTS) treatment on the induction of Th1, Th17, and Treg subsets post CFA immunization. **(A)** Representative flow cytometry plots of intracellular staining for Th1 and Th17 cytokines producing CD4<sup>+</sup> T cells. **(B)** Bars represent the percentage (mean  $\pm$  SD) of the indicated Th-subsets in spleens of the various rat groups harvested at day 20 post CFA immunization ( $n = 5$  per group). **(C)** Representative flow cytometry plots for Treg cells identification (CD3<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> events). **(D)** Left hand Bars graph represent the percentage (mean  $\pm$  SD) of Treg cells in the various rat groups ( $n = 5$  per group). Right hand plot represents the Treg to Th17 ratio in these rats. Statistical significance was assessed by one way ANOVA with *post hoc* Bonferroni's multiple comparison test (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , and \*\*\* $P \leq 0.001$ ).

The combined FTS and MTX therapy only induced a marginally significant reduction in the percentage of Th1 cells as compared to FTS alone therapy (**Figures 4A,B**). Our results suggest that the improved clinical outcome produced by FTS therapy is less dependent on the inhibition of Th1 polarization.

As the balance between the inductions of antigen-specific pathogenic Th17 versus peripheral CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells (Treg) can influence the outcome of the T cell response (47), we also determined the percentage of Treg cells in the spleens of the various rats. We found a statistically insignificant trend of increased Treg cells percentage in the spleens of FTS and FTS + MTX treated rats vs. CMC treated control arthritic rats (**Figures 4C,D**). Importantly, the ratio of Treg to Th17 cells was significantly increased ( $P < 0.01$ ) when FTS and MTX therapy were combined, but not by the single drug therapy with either FTS or MTX ( $P = 0.07$ ).

### FTS Therapy Modulates the Bhs65-Induced Inflammatory Genes Expression Program of CD4<sup>+</sup> T Cells from Treated Rats

The mycobacterial heat-shock protein 65 (Bhs65), present in CFA, has been implicated in the immune-pathogenesis of AIA (41, 48). Hence, we used *in vitro* antigenic re-stimulation with Bhs65 as an additional approach to study the effects of FTS therapy on the antigen-specific T cell response at the molecular level. Briefly, following immunization with CFA the animals were treated with FTS or CMC vehicle. At day +12 (onset of obvious clinical arthritis), the rats were euthanized, spleen, and draining superficial inguinal and para-aortic LN were harvested, and a single-cell suspension of a mixture of spleen and LN cells was prepared. Subsequently, the cells were cultured for four days with or without recombinant Bhs65 protein (5  $\mu$ g/ml), as previously described (49) and total RNA was purified at termination of the experiment.

To gain a more comprehensive insight into the gene networks that are associated with the therapeutic action of Ras-inhibitor in AIA, we analyzed by GeneChip<sup>®</sup> microarrays the changes in global gene expression (primarily mRNAs) associated with FTS treatment. Thus, at day +12, we purified CD4<sup>+</sup> T cells from the spleen and relevant draining LNs of FTS treated and control rats, re-stimulated them with Bhs65 *in vitro* and then cultured them for additional 4 days. At the end of experiment, total RNA was purified and used for the downstream transcriptome analysis.

The bioinformatics analysis of the various CD4<sup>+</sup> T cell samples showed that the antigenic re-stimulation with Bhs65, as expected, induced a robust upregulation of multiple ( $n = 50$ ) genes in CD4<sup>+</sup> T cells (**Figure 5A**). As seen in the plotted heat

map, depicting the signal intensity of the list of Bhs65-induced and differentially expressed genes (transcripts with  $\geq$ twofold change; 2FC) in CD4<sup>+</sup> T cells of CMC as well as FTS treated rats. The plot shows a widespread FTS-dependent reduction in the intensity of the Bhs65-induced transcription of a large percentage of these 50 genes ( $P < 0.001$ , by chi-square test). Notably, this list includes a large number of recognized immune response genes, such as genes encoding pro-inflammatory cytokines (e.g., IL22, IL17a/f, IFN $\gamma$ , CSF2/GM-CSF, LTA, and IL1a).

Next, to determine, in unbiased manner, the biological processes and molecular functions that mediate the therapeutic effect of FTS, we performed additional in-depth bioinformatics analysis. Thus, we computed the overlaps between our gene list and relevant annotated gene sets within the HALLMARK and gene ontology (GO) collections of the Molecular Signatures Database of the Broad Institute (Massachusetts Institute of Technology) using the GSEA software web site v6.1 (50).

By this analysis, we determined that the list of genes upregulated significantly ( $>$ twofold change, FDR  $q < 0.05$ ) following Bhs65 re-stimulation of CD4<sup>+</sup> T cells isolated from CMC treated control rats exhibited significant overlap with a large number of curated relevant immune response and cell proliferation gene sets. The top overlapping annotated gene sets included: (i) cytokine activity (GO); immune system processes (GO); G2M\_checkpoint (HALLMARK); inflammatory response (HALLMARK); response to tumor necrosis factor (GO); response to IFN- $\gamma$  (GO); positive regulation of cell proliferation (GO); IL6\_JAK\_STAT3\_signaling (HALLMARK); K-RAS signaling up (HALLMARK); and others (see also **Figure 5B**).

To validate our GeneChip<sup>®</sup> data, we analyzed by qPCR the relative quantity of mRNA transcripts of five highly relevant inflammatory response genes differentially induced by Bhs65 re-stimulation in CMC vs. FTS treated CD4<sup>+</sup> T cells (ccl20, il22, il17a, il17f, and Csf2). As shown in **Figure 5C**, the qPCR data confirmed that the induced transcription of all these genes, during the recall response of TH cells to Bhs65, was significantly inhibited by FTS therapy ( $P < 0.05$ , by *t*-test). In agreement with our gene transcription data, we also detected by ELISA a strong induction of IL-17A and IL-22 protein expression following *in vitro* Bhs65 re-stimulation of control CD4<sup>+</sup> T cells (**Figure 5D**), whereas this antigen-dependent induction of IL-17A and IL-22 secretion was strongly inhibited in equivalent cultures of FTS treated rats ( $P < 0.001$ , by *t*-test).

### The FTS Derivative 5-Fluoro-FTS (F-FTS) Shows a Higher Therapeutic Effect than FTS

Fluoro-FTS, although presumed to have a rather similar mechanism of action as the parent compound, has been previously




FIGURE 5 | Continued

**FIGURE 5 | Continued**

Farnesylthiosalicylic acid (FTS) therapy down modulates the Bhsp65-induced transcription of multiple genes tightly linked to inflammatory and immune processes. Following CFA-immunization, rats were treated with carboxymethyl cellulose (CMC) or FTS starting from day +1 post AIA induction. Single cell suspensions from draining LNs and spleen of treated rats (harvested on day +14 post disease induction) were stimulated with Bhsp65 (5 µg/ml) or control PBS and cultured for additional 72 h. At the end of cultures, CD4<sup>+</sup> T cells were isolated and high quality total RNA was extracted from the purified cells. **(A)** Heat map analysis depicting the expression matrix of the 50 genes significantly induced by Bhsp65 stimulation (>2FC, FDR  $q < 0.05$ ) in the CMC control group as compared to their expression in FTS treated group ( $n = 2$  per group). In this two-color heat map, the brightest red and green colors represent the top up- or down-regulated mRNAs, respectively. **(B)** Next, we computed using the GSEA software web site v6.1 software, the overlaps between our gene list and relevant validated gene sets. Bars represent the FDR  $q$ -value (cutoff of  $<0.05$ ) for the statistical significance of the overlap between the annotated Gene set and our list. **(C)** Purified total RNA was analyzed by quantitative PCR for the relative mRNA expression (normalized to Actb) of five inflammatory response genes (Ccl20, Il22, Il17A, Il17F, and Csf2) induced by Bhsp65 re-stimulation of CD4<sup>+</sup> T cells treated *in vivo* with CMC vs. FTS. **(D)** Supernatants from the same cultures were tested by ELISA kits for levels of secreted 17A and IL-22 by readymade ELISA kits. Bar graphs depict mean  $\pm$  SD, and statistical significance was analyzed by Student's  $t$ -test (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , and \*\*\* $P \leq 0.001$ ). Data shown are representative of a typical experiment out of  $n = 3$ .

shown to be a more potent inhibitor of oncogenic Ras signaling as compared to FTS (51). Moreover, F-FTS treatment was previously shown to strongly attenuate the development of type-1 diabetes in NOD mice (36). However, the *in vivo* therapeutic efficacy of F-FTS and FTS has not been previously compared. Thus, we designed a set of experiments to investigate the relative therapeutic efficacy of F-FTS compared to FTS. The data from these studies demonstrate that both F-FTS and FTS therapy following CFA immunization produced a significant attenuation of disease development and severity, as assessed by the clinical score and ankle joint diameter measurements, as compared to CMC treated control rats. Importantly, the therapeutic efficacy of F-FTS was significantly superior compared to FTS (**Figure 6A**). Next, we show that F-FTS therapy produced a robust reduction of serum IL-17 and IL-22 levels post CFA immunization, as compared to control immunized rats (**Figure 6B**). Moreover, the inhibitory effect on IL-22 induction was more pronounced with F-FTS vs. FTS therapy ( $P < 0.001$ , by  $t$ -test).

Next, we analyzed the effect of F-FTS therapy on the induction of antigen-specific Th17 cells. Thus, as already detailed above we employed *in vitro* antigenic re-stimulation with Bhsp65 to test this question. Our results demonstrated that *in vivo* therapy with either F-FTS or FTS was coupled with significant inhibition of IL-17 production during the recall response of Bhsp65-specific T cells compared to the robust IL-17 recall response in control CMC treated rats cultures ( $P < 0.001$  for both drugs vs. CMC, by one-way ANOVA). Moreover, as shown in **Figure 6C**, F-FTS was a more potent inhibitor compared to FTS ( $P < 0.05$ ), which positively correlated with its superior therapeutic efficacy.

## DISCUSSION

In this study, we further demonstrate the therapeutic efficacy of the orally active small-molecule inhibitors of PM-localization of Ras GTPases, FTS, and its more potent derivative F-FTS, in the rat AIA model of RA. Therapy with either FTS or F-FTS significantly reduced ankle swelling and clinical arthritis scores. Moreover, the therapeutic efficacy of Ras inhibitors was comparable to that of the mainstay disease modifying anti-rheumatic drug (DMARD), MTX. Importantly, FTS treatment as an add-on to MTX therapy resulted in a robust attenuation of arthritis development. The histopathological assessment of the ankle joints confirmed that FTS treatment reduced ankle joint inflammation and bone resorption. The clinical efficacy of the Ras inhibitors strongly correlated with reduced serum levels of IL-17 and IL-22 together


with a reduced recall Th17-response to Bhsp65-antigen stimulation in splenocytes from FTS or F-FTS treated rats. Moreover, the bioinformatics of the gene microarrays further demonstrated the wide-ranging efficacy of FTS to down-modulate the TCR activation induced transcription of a large set of canonical pro-inflammatory genes in effector CD4<sup>+</sup> T cells following *in vitro* Bhsp65 re-challenging.

Initial findings in a previous study showed that FTS treatment reduced the clinical arthritis score in the AIA model, and that this treatment was associated with reduced levels of various pro-inflammatory cytokines (IFN- $\gamma$ , TNF- $\alpha$ , IL-6, and IL-17) in the serum at study end. Our current work was designed to obtain new and pertinent data on the effects of oral Ras inhibitors on the pathogenic T cell response to CFA, and more specifically to the arthritogenic mycobacterial antigen, Bhsp65. We also provide new insight on the molecular effects of *in vivo* Ras-signaling blockade on the transcriptomes of Bhsp65-specific CD4<sup>+</sup> T cells. In the present study, we also tested in parallel the therapeutic effects of F-FTS (FTS derivative) and of FTS as an add-on to the drug MTX.

The Ras family of GTPases play an important role in signaling nodes downstream to TCR and CD28 activation (52). Perturbation of K-Ras-signaling lowers the threshold for TCR activation and thus may support abnormal responses to autoantigens (10). For example, somatic mutation in NRAS or KRAS genes in hematopoietic cells can cause a rare autoimmune disorder, characterized by lymphadenopathy and splenomegaly due to abnormal expansion of lymphocytes (53, 54). Therefore, our working hypothesis was that our Ras inhibitors might chiefly target the T cell response to CFA injection. As extensive research in murine arthritis models strongly indicates a central role for the Th17-type cells (55, 56), we focused on the effects of FTS on the induction of the Th17 response.

Our data indeed show that CFA injection was linked to a robust induction of Th17 cells, and that importantly FTS therapy reduced the frequency of Th17 cells in relevant lymphoid tissues (draining LNs and spleen). The two chief CD4<sup>+</sup> T cells subsets suppressed by FTS were IL17<sup>+</sup> (classical Th17 cells) and IL-17<sup>+</sup>IFN- $\gamma$ <sup>+</sup> “double positive” cells. The inhibitory effect on the induction of these IL-17 producing T cell subsets was comparable to the effect of MTX therapy, while the combined FTS and MTX was significantly more potent in this regard. In contrast, FTS therapy had no significant effect on the induction IFN- $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells (classical Th1 cells). Accordingly, we also detected reduced serum IL-17 levels at arthritis onset in FTS treated rats. Moreover,





**FIGURE 6 |** Fluoro-FTS (F-FTS) is significantly more effective than farnesylthiosalicylic acid (FTS) in attenuating multiple outcome measures of AIA. **(A)** Rats immunized with CFA were treated starting day +1 with either oral FTS (100 mg/kg), F-FTS (60 mg/kg), or 0.5% carboxymethyl cellulose (CMC) vehicle solution. Arthritis severity was graded by clinical scores (left panel) and ankle diameter (right panel). Statistical analysis of the AUC of the effect of the treatments on the clinical outcomes was done by one way ANOVA with *post hoc* Bonferroni's multiple comparison test, and the results are summarized in the table insets. **(B)** Sera from rats treated with either CMC, FTS, or F-FTS ( $n = 5$  per group) were collected at day +14 and analyzed for IL-17A and IL-22 levels by readymade ELISA kits. **(C)** In paralleled, single cell suspensions from draining LNs and spleen of the various rats were stimulated with Bhs65 (5  $\mu$ g/ml) of or vehicle and cultured for additional 72 h. At culture termination, we analyzed the supernatants for the levels of Bhs65-induced 17A secretion by ELISA. One representative experiments out of two performed. Bar graphs depict mean  $\pm$  SD. Statistical significance was assessed by the Student's *t*-test (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , and \*\*\* $P \leq 0.001$ ).

FTS and F-FTS therapy strongly attenuated Bhs65-induced IL-17 production by CD4<sup>+</sup> T cells (both per ELISA and per GeneChip<sup>®</sup> array data).

Although the prototype Th17 cell cytokines, IL-17A/F, have been strongly linked to autoimmunity in multiple animal models, there has been recent evidence that a fraction of Th17 cells also co-express IFN- $\gamma$  at the site of inflammation with reported functional consequences (57). Our data are the first work that

shows that CFA immunization induces significant expansion of both classical Th17 cells and Th cells with a Th17/Th1 "double phenotype." Moreover, we clearly determine by intracellular cytokine staining that FTS treatment strongly targets the expansion of this unique and likely pathogenic T cell subset in relevant lymphoid tissues.

By functional enrichment analysis of the GeneChip<sup>®</sup> array data, utilizing the GSEA platform (50), we identified a list

of validated immune/inflammatory response genes that are “silenced” by FTS therapy specifically in pathogenic CD4<sup>+</sup> Th cells responding to Bhp65. For example, besides the classical Th17 cytokine genes (*Il7* and *Il22*), we also identified that FTS targeted other pro-inflammatory cytokine genes (e.g., *Ifng*, *Cfs2*, *Lta*, *Il1a*) as well as chemokines genes that are chemotactic for effector T cells, monocytes, and dendritic cells (*Ccl1*, *Ccl20*, *Ccl7*, and *Ccl22*). Thus, these data allowed us to discover additional interesting genes, molecular processes, and biological pathways that expand our insight into the mechanism of action of FTS.

The Th17-allied cytokine IL-22 has been shown to play a pathogenic role in murine models of arthritis, particularly in promoting the early inflammatory responses to CFA and enhancing cartilage and bone damage (58–60). Moreover, levels of IL-22 and Th22 cells are increased in the synovial tissue and in the blood of RA patients, and correlate with disease activity (61, 62). Importantly, IL-22 mainly secreted locally by T cells, can induce synovial fibroblasts’ proliferation and RANKL (Receptor Activator of NF- $\kappa$ B Ligand) expression, and consequently promote their differentiation into osteoclasts (63). Our data clearly show that *in vivo* treatment with Ras inhibitors strongly attenuated the CFA-induced upregulation of serum IL-22 as well as the transcription and secretion of IL-22 by purified effector CD4<sup>+</sup> T cells re-challenged *in vitro* with the mycobacterial antigen, Bhp65.

Our novel finding that the combined MTX and FTS treatment was more potent, both by clinical and laboratory outcome measures, as compared to monotherapy with either drug alone in AIA, is highly relevant to RA treatment. MTX is commonly referred to as the cornerstone of modern RA therapy as a large percentage of patients are effectively treated with MTX alone or in combination with other drugs. Moreover, the majority of anti-RA biologics are more effective as a combination therapy with a conventional DMARD, predominantly MTX, as compared to biologics monotherapy (64). Thus, our findings strongly fit into this clinical concept: i.e., combination therapy with MTX is superior to monotherapy with the targeted-synthetic immunomodulatory compound, FTS.

Additionally, we performed for the first time a “head-to-head” comparison of the therapeutic efficacy of F-FTS vs. FTS. Our findings demonstrate that F-FTS has a superior therapeutic efficacy compared to its parent compound, FTS, at a lower dose (60 mg/kg compared to 100 mg/kg, respectively). Moreover, our ELISA data

show, in agreement with the clinical outcome data, that F-FTS was a more potent inhibitor of the *in vivo* Th17 response to CFA injection. Thus, the results from the latter set of studies add to the translational impact of the paper.

In conclusion, FTS and F-FTS, two targeted synthetic Ras-GTPases inhibitors, exhibited a potent immunomodulatory effect in the classical animal model of arthritis, AIA, which was further enhanced by combination therapy with MTX. The therapeutic effect was coupled with *in vivo* inhibition of CFA-induced generation of Th17-polarized, IL-17 and IL-22 secreting, lymphocytes. Thus, Ras-signaling-blockade is a promising novel therapeutic approach for RA, justifying further preclinical evaluation of these compounds in RA patients.

## ETHICS STATEMENT

All animal experiments were conducted in accordance with relevant laws of the state of Israel and guidelines of the Tel-Aviv University and approved by the Institutional Animal Care and Use Committee (Approval # L-14-018), and by the USAMRMC Animal Care and Use Review Office (protocol PR130028.03).

## AUTHOR CONTRIBUTIONS

MZ, VM-M, YK, and IG designed the research and analyzed data; MZ, VM-M, EV, GE-S, and JJ-H performed the research; YK and IB contributed new reagents/analytic tools; and MZ and IG wrote the paper. IG approved the final version of the manuscript.

## ACKNOWLEDGMENTS

We thank, Ben Moshe Yitzhak for excellent technical support. This work was performed in partial fulfillment of the requirements for the Ph.D. degree of MZ from the Sackler School of Medicine at Tel Aviv University.

## FUNDING

This work was supported by the U.S Department of Defense (grant numbers AMRMC W81XWH-14-1-0609 and W81XWH-14-1-0610).

## REFERENCES

1. Klarenbeek NB, Kerstens PJ, Huizinga TW, Dijkman BA, Allaart CF. Recent advances in the management of rheumatoid arthritis. *BMJ* (2010) 341:c6942. doi:10.1136/bmj.c6942
2. Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. *Trends Pharmacol Sci* (2014) 35:493–500. doi:10.1016/j.tips.2014.07.006
3. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. *Gastroenterology* (2007) 132:2359–70. doi:10.1053/j.gastro.2007.03.104
4. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* (2005) 201:233–40. doi:10.1084/jem.20041257
5. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. *J Immunol* (2003) 171:6173–7. doi:10.4049/jimmunol.171.11.6173
6. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. *Arthritis Rheum* (2002) 46:802–5. doi:10.1002/art.10173
7. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4<sup>+</sup> T cells. *Science* (1996) 271:1276–8. doi:10.1126/science.271.5253.1276
8. Schwartz RH. T cell anergy. *Annu Rev Immunol* (2003) 21:305–34. doi:10.1146/annurev.immunol.21.120601.141110
9. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase- $\alpha$ . *Nat Immunol* (2006) 7:1166–73. doi:10.1038/ni1206-1343a

10. Singh K, Deshpande P, Li G, Yu M, Pryshchep S, Cavanagh M, et al. K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis. *Proc Natl Acad Sci U S A* (2012) 109:E1629–37. doi:10.1073/pnas.1117640109
11. Singh K, Deshpande P, Pryshchep S, Colmegna I, Liarski V, Weyand CM, et al. ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. *J Immunol* (2009) 183:8258–67. doi:10.4049/jimmunol.0901784
12. Rainy N, Chetrit D, Rouger V, Vernitsky H, Rechavi O, Marguet D, et al. H-Ras transfers from B to T cells via tunneling nanotubes. *Cell Death Dis* (2013) 4:e726. doi:10.1038/cddis.2013.245
13. Rechavi O, Goldstein I, Vernitsky H, Rotblat B, Kloog Y. Intercellular transfer of oncogenic H-Ras at the immunological synapse. *PLoS One* (2007) 2:e1204. doi:10.1371/journal.pone.0001204
14. Vernitsky H, Rechavi O, Rainy N, Besser MJ, Nagar M, Schachter J, et al. Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. *J Immunol* (2012) 189:4361–70. doi:10.4049/jimmunol.1200019
15. Bos JL. Ras oncogenes in human cancer: a review. *Cancer Res* (1989) 49:4682–9.
16. Cox AD, Der CJ. Ras history: the saga continues. *Small GTPases* (2010) 1:2–27. doi:10.4161/sqtp.1.1.12178
17. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. *Recent Pat Anticancer Drug Discov* (2008) 3:31–47. doi:10.2174/157489208783478702
18. Kloog Y, Cox AD. Ras inhibitors: potential for cancer therapeutics. *Mol Med Today* (2000) 6:398–402. doi:10.1016/S1357-4310(00)01789-5
19. Kloog Y, Cox AD. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. *Semin Cancer Biol* (2004) 14:253–61. doi:10.1016/j.semcancer.2004.04.004
20. Kloog Y, Cox AD, Sinensky M. Concepts in Ras-directed therapy. *Expert Opin Investig Drugs* (1999) 8:2121–40. doi:10.1517/13543784.8.12.2121
21. Arozarena I, Calvo F, Crespo P. Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. *Genes Cancer* (2011) 2:182–94. doi:10.1177/1947601911409213
22. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. *Cell* (1999) 98:69–80. doi:10.1016/S0092-8674(00)80607-8
23. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. *Cell* (1989) 57:1167–77. doi:10.1016/0092-8674(89)90054-8
24. Gana-Weisz M, Haklai R, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. *Biochem Biophys Res Commun* (1997) 239:900–4. doi:10.1006/bbrc.1997.7582
25. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalicylic acid. *J Biol Chem* (1995) 270:22263–70. doi:10.1074/jbc.270.38.22263
26. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. *J Biol Chem* (2002) 277:37169–75. doi:10.1074/jbc.M205698200
27. Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME, et al. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. *Cancer Res* (2011) 71:2140–51. doi:10.1158/0008-5472.CAN-10-2887
28. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. *Oncogene* (2001) 20:7486–93. doi:10.1038/sj.onc.1204950
29. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1 (L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. *Cancer Res* (2004) 64:3112–8. doi:10.1158/0008-5472.CAN-04-0026
30. Ashery U, Yizhar O, Rotblat B, Elad-Sfadia G, Barkan B, Haklai R, et al. Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch. *Cell Mol Neurobiol* (2006) 26:471–95. doi:10.1007/s10571-006-9059-3
31. Charette N, De Saeger C, Horsmans Y, Leclercq I, Starkel P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. *Cell Death Dis* (2013) 4:e471. doi:10.1038/cddis.2012.200
32. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Starkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. *Mol Cancer* (2010) 9:256. doi:10.1186/1476-4598-9-256
33. Schneider-Merck T, Borbath I, Charette N, De Saeger C, Abarca J, Leclercq I, et al. The Ras inhibitor farnesylthiosalicylic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. *Eur J Cancer* (2009) 45:2050–60. doi:10.1016/j.ejca.2009.04.014
34. Aizman E, Mor A, Chapman J, Assaf Y, Kloog Y. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. *J Neuroimmunol* (2010) 229:192–203. doi:10.1016/j.jneuroim.2010.08.022
35. Karussis D, Abramsky O, Grigoriadis N, Chapman J, Mizrahi-Koll R, Niv H, et al. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. *J Neuroimmunol* (2001) 120:1–9. doi:10.1016/S0165-5728(01)00385-X
36. Aizman E, Mor A, George J, Kloog Y. Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells. *Eur J Pharmacol* (2010) 643:139–44. doi:10.1016/j.ejphar.2010.06.029
37. Oron T, Elad-Sfadia G, Haklai R, Aizman E, Brazowski E, Kloog Y, et al. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid. *Dig Dis Sci* (2012) 57:320–6. doi:10.1007/s10620-011-1880-y
38. Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, Wang N, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). *Clin Exp Immunol* (2001) 126:570–7. doi:10.1046/j.1365-2249.2001.01674.x
39. Aizman E, Blacher E, Ben-Moshe O, Kogan T, Kloog Y, Mor A. Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines. *Clin Exp Immunol* (2014) 175:458–67. doi:10.1111/cei.12235
40. Bendele A. Animal models of rheumatoid arthritis. *J Musculoskelet Neuronal Interact* (2001) 1:377–85.
41. Mia MY, Kim EY, Satpute SR, Moudgil KD. The dynamics of articular leukocyte trafficking and the immune response to self heat-shock protein 65 influence arthritis susceptibility. *J Clin Immunol* (2008) 28:420–31. doi:10.1007/s10875-008-9205-4
42. van Eden W, Thole JE, van der Zee R, Noordzij A, van Embden JD, Hensen EJ, et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. *Nature* (1988) 331:171–3. doi:10.1038/331171a0
43. Cobelens PM, Heijnen CJ, Nieuwenhuis EE, Kramer PP, van der Zee R, van Eden W, et al. Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. *Arthritis Rheum* (2000) 43:2694–702. doi:10.1002/1529-0131(200012)43:12<2694::AID-ANR9>3.0.CO;2-E
44. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, et al. Animal models of arthritis: relevance to human disease. *Toxicol Pathol* (1999) 27:134–42. doi:10.1177/019262339902700125
45. Giffen PS, Turton J, Andrews CM, Barrett P, Clarke CJ, Fung KW, et al. Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. *Arch Toxicol* (2003) 77:392–402. doi:10.1007/s00204-003-0458-7
46. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. *Arch Immunol Ther Exp* (2015) 63:435–49. doi:10.1007/s00005-015-0344-z
47. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. *Autoimmun Rev* (2014) 13:668–77. doi:10.1016/j.autrev.2013.12.004
48. Huang MN, Yu H, Moudgil KD. The involvement of heat-shock proteins in the pathogenesis of autoimmune arthritis: a critical appraisal. *Semin Arthritis Rheum* (2010) 40:164–75. doi:10.1016/j.semarthrit.2009.10.002
49. Yu H, Lu C, Tan MT, Moudgil KD. Comparative antigen-induced gene expression profiles unveil novel aspects of susceptibility/resistance to adjuvant arthritis in rats. *Mol Immunol* (2013) 56:531–9. doi:10.1016/j.molimm.2013.05.230
50. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* (2005) 102:15545–50. doi:10.1073/pnas.0506580102
51. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D, Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.

- Biochim Biophys Acta* (1998) 1406:40–50. doi:10.1016/S0925-4439(97)00077-X
52. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol* (2013) 13:227–42. doi:10.1038/nri3405
  53. Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. *Blood* (2011) 117:2883–6. doi:10.1182/blood-2010-07-295501
  54. Oliveira JB. The expanding spectrum of the autoimmune lymphoproliferative syndromes. *Curr Opin Pediatr* (2013) 25:722–9. doi:10.1097/MOP.0000000000000032
  55. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. *Nat Rev Drug Discov* (2012) 11:763–76. doi:10.1038/nrd3794
  56. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. *Nat Rev Rheumatol* (2015) 11:562. doi:10.1038/nrrheum.2015.128
  57. Kurschus FC, Croxford AL, Heinen AP, Wortge S, Ielo D, Waisman A. Genetic proof for the transient nature of the Th17 phenotype. *Eur J Immunol* (2010) 40:3336–46. doi:10.1002/eji.201040755
  58. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. *Arthritis Rheum* (2009) 60:390–5. doi:10.1002/art.24220
  59. Marijnissen RJ, Koenders MI, Smeets RL, Stappers MH, Nickerson-Nutter C, Joosten LA, et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. *Arthritis Rheum* (2011) 63:2939–48. doi:10.1002/art.30469
  60. Pineda MA, Rodgers DT, Al-Riyami L, Harnett W, Harnett MM. ES-62 protects against collagen-induced arthritis by resetting interleukin-22 toward resolution of inflammation in the joints. *Arthritis Rheumatol* (2014) 66:1492–503. doi:10.1002/art.38392
  61. da Rocha LF Jr, Duarte AL, Dantas AT, Mariz HA, Pitta Ida R, Galdino SL, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. *J Rheumatol* (2012) 39:1320–5. doi:10.3899/jrheum.111027
  62. Zhao L, Jiang Z, Jiang Y, Ma N, Zhang Y, Feng L, et al. IL-22+ CD4+ T cells in patients with rheumatoid arthritis. *Int J Rheum Dis* (2013) 16:518–26. doi:10.1111/1756-185X.12099
  63. Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. *Arthritis Rheum* (2012) 64:1015–23. doi:10.1002/art.33446
  64. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* (2017) 76:960–77. doi:10.1136/annrheumdis-2016-210715

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Zayoud, Marcu-Malina, Vax, Jacob-Hirsch, Elad-Sfadia, Barshack, Kloog and Goldstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.






Figure 1

**Disclosure of Interest:** None declared  
**DOI:** 10.1136/annrheumdis-2017-eular.1429

#### FRI0081 A MACAQUE MODEL OF RHEUMATOID ARTHRITIS BY IMMUNIZATION WITH CITRULLINATED PEPTIDES: LESSONS FOR THE HUMAN DISEASE

S. Bitoun<sup>1</sup>, P. Roques<sup>2</sup>, T. Larcher<sup>3</sup>, G. Nocturne<sup>1</sup>, C. Serguera<sup>4</sup>, P. Chretien<sup>5</sup>, G. Serre<sup>6</sup>, R. Le Grand<sup>7</sup>, X. Mariette<sup>1</sup>. <sup>1</sup>Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, INSERM U1184, le Kremlin Bicêtre; <sup>2</sup>Immunology of viral infections and autoimmune diseases, CEA, Fontenay aux Roses; <sup>3</sup>INRA UMR703 Veterinary School of Nantes, Nantes; <sup>4</sup>MIRCEN, CEA/INSERM, Fontenay aux Roses; <sup>5</sup>AP-HP, Hôpitaux Universitaires Paris-Sud, le Kremlin Bicêtre; <sup>6</sup>INSERM U1056 - Université de Toulouse Paul, Toulouse; <sup>7</sup>CEA - Université Paris Sud 11 - INSERM U1184, Fontenay aux Roses, France

**Background:** Recent evolution in the understanding of rheumatoid arthritis (RA) mechanisms is the role of antibodies directed against citrullinated (cit) proteins (ACPAs). The shared epitope (SE) on the MHC class II is the main genetic risk factor of RA and favors presence of ACPAs. Mouse models dependent on cit peptides immunization require transgenic expression of the SE and are controversial. Non-human primates are ideal to study the interaction between ACPA and RA since 8% carry, similarly to humans, the SE called the H6 haplotype.

**Objectives:** The goal of this study was to develop a new animal model of RA based on immunization of genetically predisposed macaques against cit peptides to generate an ACPA-mediated model of arthritis.

**Methods:** Six macaques were intra dermally (ID) immunized with 4 peptides: vimentin (59–71) and (66–78),  $\alpha$  fibrinogen (79–91) and aggrecan (89–103). H6 animals were immunized with either cit (n=2) or arginine (arg) (n=2) containing peptides. Two non H6 animals were immunized with cit peptides. These peptides are known to induce a T cell response in RA patients carrying the SE. T-cell response was assessed with Interferon  $\gamma$  ELISPOT and B-cell response by ELISA. An intra articular (IA) boost was done 30 weeks after initial immunization with either incomplete Freund's adjuvant (IFA) alone, IFA and cit peptides and IFA plus non relevant peptides.

**Results:** In the macaques, the T-cell response was specific to cit or arg peptides (depending on the peptides used for immunization). Surprisingly, the presence of the H6 epitope did not influence the response. Conversely the antibodies generated in response to the peptides were cross-reactive between the cit and arg peptides. Since no clinical response was observed, an IA boost was performed with the same 4 cit peptides and IFA adjuvant. This led to a prolonged neutrophil-rich mono-arthritis preferentially in H6 animals (Figure). Conversely, animals



boosted with IFA alone only or with IFA plus myelin oligodendrocyte glycoprotein (MOG) peptides and previously immunized with MOG peptides presented with a transient mono-arthritis. Histological analysis revealed a local mononuclear infiltrate in one of the two animals that had prolonged knee monoarthritis. There was no clinical polyarthritis but 2 animals displayed synovial proliferation in 1 MCP and 1 MTP, respectively.

**Conclusions:** Immunization of macaques with cit peptides, then IA boost with the same cit peptides plus IFA, induced a prolonged monoarthritis. Shared epitope bearing did not restrict the T-cell response but seemed to favor the prolonged swelling after the IA boost. Neutrophil infiltration of the joint occurred similarly to what is seen in RA. Further use of neutrophil chemo-attractant might lead to a poly-articular disease. This macaque model of RA appears unique to study the events occurring during the pre-clinical phase of RA.

**Disclosure of Interest:** None declared  
**DOI:** 10.1136/annrheumdis-2017-eular.2843

#### FRI0082 RAS SIGNALING INHIBITORS ATTENUATE ARTHRITIS IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY DOWN MODULATING THE PATHOGENIC TH17 CELL RESPONSE

M. Zayoud<sup>1,2</sup>, E. Vax<sup>1</sup>, G. Elad Sfiadia<sup>3</sup>, V. Marcu-Malina<sup>1</sup>, Y. Kloog<sup>3</sup>, I. Goldstein<sup>1,2,4</sup>. <sup>1</sup>Immunology Core Laboratory, Chaim Sheba Academic Medical Center, Ramat Gan; <sup>2</sup>Medicine, Sackler Faculty of Medicine, Tel Aviv University; <sup>3</sup>Faculty of Life Sciences, Tel Aviv University, Tel Aviv; <sup>4</sup>Rheumatology, Chaim Sheba Academic Medical Center, Ramat Gan, Israel

**Background:** Ras-GTPases are vital for normal T cell activation, and downstream effectors of Ras include the MEK/ERK, PI3-kinase/AKT, mTOR/p70S6-kinase, and NF- $\kappa$ B pathways. Somatic mutations in NRAS cause an autoimmune lymphoproliferative disorder and T cells from Rheumatoid Arthritis (RA) patients exhibit perturbation of the Ras/MEK/ERK pathway. The small molecule Farnesylthiosalicylic acid (FTS) inhibits the interaction between Ras-GTPases and prenyl-binding chaperones vital for proper plasma membrane localization and downstream signaling [1]. Previous pre-clinical studies suggest that FTS has an immunomodulatory effect in various animal models of autoimmunity [2].

**Objectives:** To test in the Lewis rat adjuvant induced arthritis (AIA) and in the DBA/1 mouse collagen type-II induced arthritis (CIA) models the therapeutic immunomodulatory effect of FTS alone or combined with methotrexate (MTX).

**Methods:** Arthritis was induced in 8–12 week old male Lewis rats by complete Freund's adjuvant (CFA) injection and in male DBA/1 mice by collagen type-II (CII) immunization. Animals were treated prophylactically with once daily oral FTS (100 mg/kg); weekly i.p injection of MTX (0.5 mg/kg), oral FTS combined with MTX, or daily oral vehicle solution (0.5% carboxy methyl cellulose; CMC). Arthritis severity was scored daily from disease onset until study termination. In addition, we measured multiple disease- and drug-related immunological/molecular biomarkers.

**Results:** AIA severity was significantly reduced by FTS treatment compared to CMC controls (Figure 1A,  $P < 0.001$ ). Combining FTS and low dose MTX significantly increased its therapeutic efficacy compared to each drug alone (Figure 1A,  $P < 0.05$ ). FTS or FTS+MTX treatment also suppressed the upsurge in serum IL-17 and CRP compared to ailing controls. Global gene expression analysis of relevant splenic CD4<sup>+</sup> T cells revealed that FTS is a potent inhibitor of pro-inflammatory and TH17 related gene networks. Next, our data from the mouse CIA model show that the therapeutic efficacy of FTS was non-inferior to MTX and it significantly reduced arthritis severity compared to controls (Figure 2,  $P < 0.001$ ). Importantly, FTS significantly inhibited the production of pathogenic anti-CII autoantibodies and upregulation of serum IL-6 and IL-17A compared to control arthritic mice. The in depth, multiplex, analysis of the effect of FTS on the T cell cytokine response to CII, revealed strong suppression of IL-22, IL-17, IL-9, GM-CSF and TNF production. Noteworthy, FTS therapy positively correlated with reduced Ras-GTP, p-ERK and p-AKT levels in splenic lymphocytes (drug related biomarkers).




Figure 1. FTS attenuates arthritis severity in the (A) rat AIA and (B) mouse CIA models

**Conclusions:** FTS, a first-in-class oral selective Ras-GTPases inhibitor, exhibits a potent immunomodulatory effect in two classical murine model of arthritis, coupled with the inhibition of the TH17 response to relevant arthritogenic-antigens. Thus, Ras-signaling-blockade is a promising novel therapeutic approach for RA.

#### References:

- [1] Kloog Y, Cox AD. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. *Semin Cancer Biol.* 2004 Aug; 14(4):253–261.

[2] Mor A, Aizman E, Chapman J, Kloog Y. Immunomodulatory properties of farnesoids: the new steroids? *Curr Med Chem*. 2013; 20(10):1218–1224.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.1083

# **FRI0083 REDUCED INCREASE OF ACPA IGG-FC GALACTOSYLATION DURING PREGNANCY IN COMPARISON TO TOTAL IGG: AN EXPLANATION WHY AUTOANTIBODY POSITIVE RA-PATIENTS IMPROVE LESS DURING PREGNANCY?**


A. Bondt<sup>1,2,3</sup>, L. Hafkenscheid<sup>3</sup>, D. Falck<sup>2</sup>, T.M. Kuijper<sup>1</sup>, Y. Rombouts<sup>3</sup>, J.M. Hazes<sup>1</sup>, M. Wuhrer<sup>2</sup>, R.J. Dolhain<sup>1</sup>. <sup>1</sup>Rheumatology, Erasmus University Medical Center, Rotterdam; <sup>2</sup>Center for Proteomics and Metabolomics; <sup>3</sup>Rheumatology, Leiden University Medical Center, Leiden, Netherlands

**Background:** Rheumatoid arthritis (RA) disease activity (DAS28-CRP) improves less during pregnancy in autoantibody positive patients.<sup>1</sup> The most specific autoantibodies for RA are anti-citrullinated protein antibodies (ACPAs), which mainly occur as the immunoglobulin (Ig) G isotype. An association with DAS28-CRP and the pregnancy-associated improvement is well established for the Fc glycosylation of total IgG, in particular for galactosylation (Gal) and sialylation (SA).<sup>2</sup> The Fc glycosylation of ACPAs – mainly present as IgG – has been reported to be different from the total IgG Fc glycosylation.<sup>3</sup>

**Objectives:** We sought to determine whether the change in ACPA IgG glycosylation during pregnancy is different from that of total IgG, and whether this relates to the improvement of RA during pregnancy.

**Methods:** ACPA positive patient sera (n=152) were obtained within the framework of the PARA cohort, a prospective study designed to investigate pregnancy-associated improvement of RA. ACPA IgG was isolated using microscale affinity chromatography. Trypsin digested ACPA IgG was measured using nano-liquid chromatography mass spectrometry, and compared to total IgG.

**Results:** Pregnancy-associated changes in the levels of glycosylation were observed for all ACPA IgG subclasses. Pregnancy-associated glycosylation changes were less pronounced during pregnancy and after delivery in ACPA IgG (Gal +5%; SA +0.5%) compared to total IgG (Gal +11%; SA +2.5%; Figure 1), but – for total IgG – not different between ACPA+ and ACPA- patients. No association of the change in DAS28-CRP with the change in ACPA IgG or total IgG galactosylation was observed for ACPA+ patients, whereas a strong association of total IgG galactosylation was observed for ACPA- patients.



**Conclusions:** During pregnancy the increase in galactosylation of ACPA IgG was less pronounced than that of total IgG, whereas the increase in the galactosylation of total IgG was not different between ACPA+ and ACPA- patients. Since it is known that changes in IgG galactosylation are associated with improvement of RA during pregnancy and since ACPA is thought to be of pathogenic significance in RA, our data might provide an explanation why ACPA+ RA patients are less likely to improve during pregnancy.

## **References:**

- Ince-Askan H, Hazes JM, Dolhain RJ. Identifying clinical factors associated with low disease activity and remission of rheumatoid arthritis during pregnancy. *Arthritis Care Res (Hoboken)* 2016 doi: 10.1002/acr.23143.
- Bondt A, Selman MHJ, Deelder AM, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. *Journal of Proteome Research* 2013;12(10):4522–31. doi: 10.1021/pr400589m.
- Scherer HU, van der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. *Arthritis Rheum* 2010;62(6):1620–29. doi: 10.1002/art.27414.

**Acknowledgements:** This project is funded by the Dutch Arthritis Foundation (NR 10–1-411) and by the European Union's Seventh Framework Program (FP7-Health-F5–2011) under grant agreement no 278535 (HighGlycan). We thank Dr Jan Wouter Drijfhout (LUMC, Leiden) for providing the CCP2 peptide.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.6229

# **FRI0084 THE TONSIL MICROBIOME IS INVOLVED IN RHEUMATOID ARTHRITIS**

J. Li<sup>1</sup>, J. He<sup>1</sup>, K. Deng<sup>2</sup>, J. Qin<sup>2</sup>, Y. Jin<sup>1</sup>, J. Chen<sup>1</sup>, Z. Li<sup>1</sup>. <sup>1</sup>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing; <sup>2</sup>Digital Microbiota Technology Co. Ltd., Shenzhen, China

**Background:** Rheumatoid arthritis (RA) is a prevalent systemic autoimmune disease characterized by the production of autoantibodies<sup>1</sup>. The tonsil has been demonstrated to be a site of citrullination, and tonsillectomy has been reported to be a potential treatment of RA, suggesting the possibility that the tonsil could be a site of autoimmunity generation in RA<sup>2,3</sup>. The dysbiosis of gut microbiome and the associated host immune response has been implicated in the initiation and progression of RA<sup>4–6</sup>. However, there is no in-depth studies on the role of tonsil microbiota in RA. Thus, studies of the characteristics of tonsil microbiome in RA patients, the underlying mechanisms, as well as specific markers for the diagnosis and therapeutic evaluation for RA, are critical for the early diagnosis and prevention of RA.

**Objectives:** Therefore, we aimed to define the association of RA with tonsil microbiome as well as a microbial and metabolite profile that could predict disease status.

**Methods:** 16S rRNA gene sequencing was utilized on 220 tonsil swab samples (121 RA patients and 99 healthy controls) as well as 78 fecal samples (68 RA and 10 controls). Analysis of microbial taxa and metabolic pathway were performed to characterise and compare the tonsil microbiome of RA patients and healthy subjects

**Results:** Results showed that the tonsil harbored a unique microbiome relative to that present in the fecal samples. Patients with RA exhibited different tonsil microbiome from controls. A taxon-level analysis suggested that the relative abundance of 26 microbial clades were significantly altered, with 7 taxa increased and 19 taxa decreased in RA samples. Noticeably, we observed an expansion of rare microbial lineages as well as an alteration in microbial cladogenesis within RA patients. RA tonsil microbiota was associated with smoke, anti-peripheral factor, rheumatoid factors, disease duration and activity. Furthermore, we identified that 86 genes associated with bacterial metabolic pathway were enriched in RA tonsil microbiome.

**Conclusions:** Our results demonstrated that the RA tonsil microbiome differs from that of healthy controls, which correlates with systemic autoimmune changes and may potentially drives initiation of RA.

## **References:**

- McInnes IB, and Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med*. 2011, 365(23): 2205–2219.
- Kawano M, Okada K, Muramoto H, et al. Simultaneous, clonally identical T cell expansion in tonsil and synovium in a patient with rheumatoid arthritis and chronic tonsillitis. *Arthritis Rheum*. 2003, 48(9): 2483–2488.
- Makrygiannakis D, af Klint E, Lundberg IE, et al. Citrullination is an inflammation-dependent process. *Ann Rheum Dis*. 2006, 65(9): 1219–1222.
- Scherer JU and Abramson SB. The microbiome and rheumatoid arthritis. *Nat Rev Rheumatol*, 2011, 7(10): 569–578.
- Scherer JU, Sczesnak A, Longman RS, et al. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *Elife*, 2013, 2:e01202.
- Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med*, 2015, 21(8): 895–905.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.4707

FRIDAY, 16 JUNE 2017

## **Rheumatoid arthritis - prognosis, predictors and outcome**

# **FRI0085 NUMBER OF PEPTIDE-SPECIFIC ANTI-CITRULLINATED PEPTIDE ANTIBODIES IN SYNOVIAL FLUID AND IN SYNOVIAL FLUID IMMUNE COMPLEXES ASSOCIATE WITH DEGREE OF RADIOLOGICAL DESTRUCTION AND RESPONSE TO TRIAMCINOLONE HEXACETONIDE FOR KNEE SYNOVITIS IN RHEUMATOID ARTHRITIS**

A. Sohrabian<sup>1</sup>, L. Mathsson Alm<sup>1,2</sup>, M. Hansson<sup>3</sup>, J. Lysholm<sup>4</sup>, M. Cornillet<sup>5</sup>, A. Knight<sup>6</sup>, K. Skriver<sup>7</sup>, G. Serre<sup>5</sup>, A. Larsson<sup>8</sup>, T. Weitoft<sup>9</sup>, J. Rönnelid<sup>1</sup>.

<sup>1</sup>Department of Immunology, Genetics and Pathology, Uppsala university; <sup>2</sup>Immunodiagnostic Division, Thermo Fisher Scientific, Uppsala; <sup>3</sup>Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm; <sup>4</sup>Clinic of Rheumatology, Falun Hospital, Falun, Sweden; <sup>5</sup>Epithelial Differentiation and Rheumatoid Autoimmunity, U 1056 Inserm Toulouse University, Toulouse, France; <sup>6</sup>Rheumatology, Department of Medical Sciences, Uppsala university, Uppsala, Sweden; <sup>7</sup>Department of Medicine, Charité University Hospital, Berlin, Germany; <sup>8</sup>Section of Clinical Chemistry, Department of Medical Sciences, Uppsala university, Uppsala; <sup>9</sup>Section of Rheumatology, Center for Research and Development, Uppsala university, Gävle, Sweden

**Background:** We have described a planar microarray for the determination



ImmunoHorizons

Now Open for Submissions



The Journal of  
Immunology

## Farnesylthiosalicylic acid reduces disease severity in the collagen type-II induced arthritis mouse model by inhibiting Ras Signaling in pathogenic T cells

Morad Zayoud, Einva Vax, Galit Elad Sfadia, Yoel Kloog and Itamar Goldstein

J Immunol May 1, 2017, 198 (1 Supplement) 224.7;

Article

Info & Metrics

### Abstract

**Background** Ras proteins are vital for normal T cell activation, and downstream effectors of Ras include the MEK/ERK, PI3-kinase/AKT, and NF- $\kappa$ B pathways. T cells from Rheumatoid Arthritis patients exhibit abnormal activation of the Ras/MEK/ERK pathway. The small molecule Farnesylthiosalicylic acid (FTS) blocks the interaction between Ras proteins and their prenyl binding chaperones, attenuating plasma membrane localization and signaling.

**Objectives** To investigate the immunomodulatory effect of FTS alone or combined with methotrexate (MTX) in the DBA/1 mouse collagen type-II induced arthritis (CIA) model.

**Methods** Arthritis was induced in 8–10 week old male DBA/1 mice by immunization with collagen type-II (CII) and complete Freund's adjuvant (CFA). Animals were treated semi-prophylactically with once daily oral FTS (100 mg/kg); weekly i.p injection of MTX (0.5 mg/kg), FTS combined with MTX, or daily oral vehicle solution (control). Arthritis severity was scored daily from disease onset until study termination and multiple immunobiological markers of inflammation were analyzed.

Continue

Find out more

**Results** Our data from the mouse CIA model show that the therapeutic efficacy of FTS was similar to MTX, and both drugs significantly reduced arthritis severity compared to CMC controls. Importantly, FTS significantly inhibited the production of pathogenic anti-CII autoantibodies and upregulation of serum IL-6 and IL-17A compared to control arthritic mice. The in depth, multiplex, analysis of the effect of FTS on the T cell cytokine response to CII, revealed strong suppression of IL-22, IL-17, IL-9, GM-CSF and TNF production. Importantly, FTS therapy positively correlated with reduced p-ERK1/2 and p-AKT levels in splenic lymphocytes.

Copyright © 2017 by The American Association of Immunologists, Inc.

[← Previous](#)

[^ Back to top](#)

## In this issue


The Journal of Immunology

Vol. 198, Issue 1 Supplement

1 May 2017

[Table of Contents](#)

 [Article Alerts](#)

 [Share](#)

 [Email Article](#)

 [Citation Tools](#)

## ▼ Related Articles

*No related articles found.*

[Google Scholar](#)

► [Cited By...](#)

► [More in this TOC Section](#)

► [Similar Articles](#)

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

[Continue](#)

[Find out more](#)